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Proteomics is the wide – scale study of proteins, in which the proteome of an organism is 
studied. Proteomics experiments obtain both qualitative and quantitative information by using a 
combination of analytical techniques including liquid chromatography, ion mobility, and mass 
spectrometry (MS). In quantitative experiments, relative protein amounts are determined to gain 
a better understanding of biological problems related to disease-state, kinetic changes, and 
effects of pharmaceutical products. In many cases, multiple samples (e.g. 10s to 100s) are 
analyzed to obtain statistically – significant results, which requires ample time (on the order of 
several days to weeks). To reduce sample analysis time and potential experimental error, 
multiplexing strategies have been developed. Samples are labeled metabolically, enzymatically, 
or chemically during sample preparation, pooled together, and analyzed simultaneously in the 
mass spectrometer.  
In this body of work, multiplexing strategies have been applied to study aging and 
response to infection in C. elegans and the involvement of the periphery in Alzheimer’s disease. 
In addition, the development of analyzing multiplexed samples on Orbitrap MS platforms will be 
presented. These developments and applications contribute to science by providing insight to two 
conditions that affect the aging population.  
Development and Applications of Enhanced Multiplexing to Better Understand Aging, 
Infection, and Alzheimer’s Disease  
Christina Dee King, Ph.D. 
University of Pittsburgh, 2018
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1.1 AGING AND IMMUNITY 
Immunonescence, the gradual decline of aging, is an inevitable process that results in 
several physiological changes, including alterations in the response from both the immediate 
(innate) and specialized (adaptive) immune responses. Within the body, changes related to 
decreases in neutrophil function,3 T cell receptor diversity,4 inflammatory cytokine production,5  
and other deficits accompany and actuate age-related immune failure. Middle-aged individuals 
exhibit defects in nearly every cell type and process required for both the innate and adaptive 
immune responses. These molecular defects also appear to be common to invertebrates.6 There is 
an increasing population of aging individuals, therefore studying the mechanisms that are 
involved in aging and infection is quite important.  
One result of a declined immune response includes a higher susceptibility of infection 
and infectious diseases from opportunistic pathogens. Some well-studied species include Gram-




aeruginosa) bacteria; S. aureus and P. aeruginosa are responsible for a significant number of 
hospital-acquired infections in immunocompromised patients.7 Specifically, infections from  P. 
aeruginosa can also result in sepsis, a systemic inflammatory response induced by an infection, 
which occurs more frequently in individuals with immunocompromised systems.7 The rapid 
evolution of P. aeruginosa and its growing antibiotic resistance makes investigations of the 
versatile strains important, especially with respect to immunosenescence.7 Better understanding 
the dynamics of host-pathogen interactions in this context could facilitate the development of 
either more effective antibiotics, or pharmaceutical enhancers of intrinsic immune function in 
high-risk patient groups. 
1.1.1 Studying Aging and Host-Response to Infection in Model Organisms 
In order to study aging, model organisms have been employed. Animal models provide a 
wealth of information in understanding the mechanisms involved in responding to infection. 
They are optimal systems for elucidating the molecular details of microbial pathogenesis and 
host immunity, and for accelerating the translation of discoveries into clinical outcomes. Models 
used to study host-response to infection include D. melanogaster (fruit fly), M. mulatta (Rhesus 
monkey), Rattus norevegicus (rat), M. musculus (mouse), and C. elegans (roundworm). In 
particular, the roundworm is an ideal model to use to study both aging and host-response to 
infection because it develops to adulthood within a few days, has large progeny (~100s), has a 
short lifespan of ~28 days, is transparent, and most importantly, its innate immune system is 




C. elegans is subject to infection by various human bacterial pathogens8, many of which 
enact infectious processes that are quite comparable, at the cellular level, to their modes of 
pathogenesis in humans.9 The capacity of multiple P. aeruginosa strains to rapidly kill C. 
elegans populations through both biofilm-like-colonization mediated infections and via secreted 
exotoxins has been thoroughly characterized.10-12 Additionally, while lacking an adaptive 
immune system, the critical regulatory elements currently known to coordinate innate immunity 
in C. elegans are highly conserved in vertebrates, such as the p38 mitogen-activated protein 
kinase (MAPK), transforming growth factor (TGF)-β, and DAF-2 insulin/IGF1 signaling 
pathways.13-15 Furthermore, C. elegans’ infection-resistance mechanisms undergo 
immunosenescent decline with age in a manner dependent on deteriorating p38 MAPK 
function.16  
Currently, C. elegans’ response to infection has been characterized at genomic-, 
transcriptomic- and proteomic- levels by full-genome microarrays, RNA-sequencing, and 
proteomics analyses. These studies have shown that specific genes are either up- or down-
regulated at the transcriptional level in response to several pathogens, including P. aeruginosa,17-
18 D. coniospora,19-20 S. aureus, S. marcescens,19 and Y. pestis.21  Proteomics analyses have also 
identified both general and pathogen – specific responses from S. aureus,22 pathogenic E. coli,23 
P. aeruginosa,24-25 and others26; however, long term proteome changes following infection are 
unknown and no studies comparing proteomic alterations in young versus old animals facing 




1.1.2  Aging and Alzheimer’s Disease 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that causes 
cognitive decline over 7-10 years.27 Symptoms include short-term memory loss and the inability 
to perform every-day tasks. As AD becomes more severe, an individual’s ability to take care of 
themself is impaired, therefore, requiring assistance from caregivers. AD is a top-ten cause of 
death in the United States that neither can be prevented nor has a cure. This condition affects 
women more frequently and cost the United States >~$200 billion to treat in 2017.27 
Comorbidities, including cardiovascular disease,28 hypertension,29 diabetes,30-32 and Down 
syndrome,33 increase the risk of developing AD, however, the largest risk factor is increasing 
age.27  
There are two types of AD that occur either early (early – onset AD) or later (late – onset 
AD) in life that result in cognitive decline. Early – onset AD is caused by mutations in amyloid 
precursor protein (APP-1), presenilin-1 (PS-1), and presenilin-2 (PS-2).34-36 The etiology of late 
– onset AD, however, is based on the formation and aggregation of amyloid-beta (Aβ) plaques.37 
AD begins to present as preclinical AD38 and develops into mild cognitive impairment (MCI)39-
40; the disorder then develops into prodromal AD41-42 and clinical AD.  Late – onset AD43 is 
prominent after 65 years of age whereas early – onset AD occurs between 30 – 50 years of age. 
Cognitive27 and neuroimaging44-48 tests, and sampling of cerebrospinal fluid (CSF) are most 
commonly performed to diagnose AD ante-mortem while classical hallmarks of AD, including 
the presence of senile Aβ plaques and neurofibrillary tangles (NFT), are identified post-mortem. 
To diagnose, treat, and potentially prevent AD, studies have been performed to identify 




changes occurring during the course of AD in both animal models and in individuals with AD 
(e.g. plasma, CSF, and post-mortem brain tissues). The most well-known genetic marker, 
apolipoprotein E, is used to determine if there is an increased susceptibility to developing AD; 
individuals with the allele type 4 are more likely to have AD than people with alleles 2 or 3.49-51 
To understand the pathogenesis of AD, a host of studies related to the genome, transcriptome, 
and proteome of AD samples have been performed. However, most of these studies have focused 
on brain tissues and CSF and they have neglected to consider the contribution of peripheral 
tissues. Such studies are warranted in order to understand the relationships with abnormalities 
and to increase the opportunities for biomarker development and therapeutic target. Below is a 
general scope of proteomics as it is used one of the major tools that can be used to better 
understand disease. 
1.2 PROTEOMICS 
Proteomics is the large-scale study of proteins. Protein extracted from tissues, plasma, 
cells, or other bodily fluids are studied by using a combination of biological and analytical 
techniques, thus yielding information about the identity and quantity of proteins present. 
Statistical tests and bio-informatics analyses identify statistically – significant proteins, 
pathways, molecular functions, and cell compartments related to disease-state and progression, 
kinetics, post-translational modifications, and other types of changes related to the organism.  
Over the past twenty five years, proteomics has grown to being able to analyze proteins in a 




in proteomics have been made possible by several contributing factors, including the 
development of soft ionization methods such as electrospray ionization (ESI)52 and matrix 
assisted laser desorption ionization (MALDI),53-54 improvements in sample preparation, and 
novel MS instrumentation.  
Currently, there are three broad sets of techniques (e.g. top-down, middle-down, or 
bottom-up) applied in proteomics. Top-down techniques analyze intact proteins to gain 
information about protein structure and protein-protein interactions. Bottom-up techniques, 
however, analyze peptide samples with MS and MS/MS and use protein-based software to obtain 
protein identifications. Specifically, the proteome database of the organism being studied is used 
to generate an in silico digest and theoretical MS/MS spectra are compared to experimentally 
obtained MS/MS spectra. Experimental spectra that are highly scored are assigned with the 
proper protein. Lastly, middle-down techniques use a combination of both top-down and bottom-
up methods to analyze proteins. In the work presented below, bottom-up proteomics has been 
especially helpful in answering biological inquiries.  
1.2.1 Bottom-up Proteomics 
Bottom-up proteomics takes information obtained about peptides and uses search 
algorithms to reference them to their respective proteins (Figure 1.1). First, protein is extracted 
from the source (e.g. cells, serum, plasma, blood, tissue, urine) and the protein concentration is 
determined by using a UV-Vis-based assay. To prevent protein modifications due to sample 
handling, protease inhibitors can be added to samples.  After protein concentration is determined, 




peptides. Typically, trypsin is used for proteolytic digestion; this enzyme cleaves at the C-
terminus of lysine and arginine residues.  Depending on the type of analysis, different enzymes 
may be used to cleave at different amino acids. For instance, Lys-C only cleaves at lysine 
residues at the C-terminus, Glu-C cleaves at the C-terminus of glutamic acid and Glu-N cleaves 
at the N-terminus of glutamic acid. Peptides are then separated using reversed-phase high 
performance liquid chromatography (RP-HPLC). To reduce sample complexity, an orthogonal 
separation technique, which allows for greater depth in analyzing the proteome(s) of interest, can 
be performed prior to RP-HPLC analysis. Methods such as ion exchange (e.g. strong cation, 
strong anion, weak cation, and weak anion) and more recently, high pH reversed phase 
fractionation (h-pH) can be performed either on- or off-line to separate peptides by charge or 



























As peptides are introduced into the mass spectrometer, they are ionized, selected, sorted 
by the mass analyzer, and detected. Peptides can be fragmented by several types of dissociation 
techniques, including collision – induced dissociation (CID), higher energy collision-induced 
dissociation (HCD), electronic capture dissociation,55 electronic – transfer dissociation,56 surface 
induced dissociation,57 photo dissociation, and electronic – transfer higher energy collision – 
induced dissociation.58 These dissociation techniques cause fragmentation at different bonds 
(Figure 1.2) along the peptide backbone using a range of energies. To fragment at the peptide 
bond (generating b and y ions), CID is applied with a range of normalized collision energies of 
20 – 35%. Inside the ion-trap, precursor ions of interest are excited by a resonance excitation RF 
voltage to gain kinetic energy. Ions collide with a neutral, buffering gas (e.g. helium), and 
convert kinetic energy into internal energy.59-60 Once ions gain enough internal energy, they 
dissociate into product ions and are detected. Another commonly used dissociation technique is 
HCD. This method is performed in a multipole collision cell in which a higher normalized 
collision energy of 50 – 60% is applied. Similar to CID, kinetic energy will be converted into 
internal energy, resulting in product ions. The advantage of this dissociation technique, however, 




























The data obtained from fragmentation spectra are analyzed using protein software, such 
as Proteome Discoverer (PD, ThermoFisher Scientific), Maxquant,61 or Skyline,62 to gain 
qualitative and quantitative information. Exported results from protein software are further 
analyzed by applying statistical tests (e.g. student t-test or one-way ANOVA) to identify 
statistically – significant proteins and bioinformatics tools are used to gain biological insight 
and/or implications of a given condition or disease. Bioinformatics tools compare the proteome 
of the organism being studied to a list of statistically – significant proteins added to the platform. 
If a significant difference of proteins related to specific gene ontology (GO) parameters (e.g. 
biological processes, molecular functions, or cell compartments) are present, then that specific 
GO term will be labeled as statistically – significant.  Bioinformatics analyses typically provide 
qualitative information about pathways that are dysregulated in disease. Quantitative proteomics 
techniques can be employed to learn more about proteins that change in a sample.  
1.2.2 Quantitative Proteomics 
  Label – free quantitative (LFQ) proteomics methods use chromatographic peak areas,63 
peptide spectral counts,64 peptide signal intensities,65-66 or a combination of peptide and spectral 
counts, and MS/MS spectra (i.e. normalized spectral index),67 gain quantitative information. 
Some benefits of using label – free methods includes increased flexibility of MS platforms for 
sample analysis, increased dynamic range, and higher proteome coverage.68 Challenges 
associated with LFQ are related to obtaining accurate quantification and sample-to-sample 
variability. Since each sample is being prepared individually, experimental error may vary 




To reduce these limitations, techniques using stable isotopes from small molecular weight 
chemical groups can be applied to protein samples. Labeling can be performed with cells, entire 
organisms, proteins, and peptides. Protein amounts are determined by either absolute or relative 
quantification, and are based on the intensity of either the tagged intact peptide or peptide 
fragment.  
At the organism or cell level, heavy isotopes are incorporated into food and fed to cells, 
worms, mice, rats, etc.70-71 After several generations of the label being incorporated, the tagging 
efficiency should be ~99%. Once this efficiency is reached, samples can be prepared using 
bottom-up proteomics techniques and analyzed. Heavy nitrogen has been demonstrated to label 
samples prior to protein homogenization.70 These heavy nitrogen atoms result in all amino acids 
being labeled at the amide bond. This method is simple and straightforward, but as all nitrogen 
atoms are labeled, quickly determining the masses of labeled peptides can be challenging. Since 
the number of nitrogen atoms present in each peptide may differ, the corresponding mass shift 
between unlabeled and heavy-labeled peptides will not be consistent, thus complicating the 
process of searching for peak pairs. In addition, this method only allows two samples to be 
multiplexed at once. To address both of these issues, stable – isotope labeling by amino acids in 
cell culture/mammals (SILAC/SILAM) can be used.71-72 SILAC/SILAM starts with using cells 
or organisms, however heavy isotopes (e.g. 13C or 15N) only label specific residues (i.e. lysine, 
arginine, leucine, and proline) with 2H, 13C, or a combination of 15N and 13C. Because labeling 
occurs at specific residues, mass shifts are more predictable. To multiplex more samples (e.g. 18 
samples), NeuCode SILAC mass tags can be incorporated.73-74 In these tags, mass differences 
resulting from neutron-binding energy variation in stable isotopes are encoded into amino 




sample. If the sample(s) are not cells or rodents, then this method cannot be used. To chemically-
label protein or peptide samples already extracted, other labeling methods can be applied. 
Protein samples arising from any origin can be labeled at either the protein or peptide 
level by using either isotopic or isobaric tagging strategies. Similar to SILAC, isotopic labeling 
methods use chemical groups that include heavy isotopes. These methods typically label the N-
terminus of peptides and lysine residues. Common labeling methods include acetylation75 and 
dimethylation.76 These methods allow between three and five samples to be analyzed at once, 
with mass shifts of at least two Da. The major challenge with isotopic labeling includes the 
potential issue with isotopic clusters between light and heavy pairs overlapping in the precursor 
scan. To circumvent this issue, heavy isotope tags with a larger mass difference (e.g. >6 Da) than 
the light tags can be used.  
Another chemical labeling strategy that can be applied is isobaric tagging. This method 
uses a chemical reagent tag that consists of a mass reporter group, a normalizing group, and a 
reactive group. Common isobaric tagging reagents include Tandem Mass Tags (TMT)77, Isobaric 
Tag for Relative and Absolute Quantification (iTRAQ)78, and N,N-Dimethyl Leucine (DiLeu)79, 
and are available commercially (TMT and iTRAQ) or may be synthesized in the laboratory 
(DiLeu). In an isobaric tagging experiment, the N-terminus of peptides and lysine residues react 
with the reactive group (e.g. N-hydroxysuccinimide) via a carbonyl attack, leaving the mass 




















































Several samples are multiplexed by performing this reaction with different variants of the 
isobaric tag (Figure 1.4). In Figure 1.4, six samples are chemically-tagged (individually) by 
using six versions of the isobaric tagging reagent. After the reactions are completed and 
quenched, tagged peptides are combined into one sample and subjected to LC – MS/MS analysis.    
A peptide present in several samples (e.g. 6 – 11) will have the same mass, therefore they 
will elute at the same time. Once a peptide is fragmented by HCD, reporter ion intensities 
corresponding to that peptide will be detected, thus providing relative quantitative information 
for that peptide. Current isobaric tagging reagents allow for 1 – 12 samples to be analyzed at 
once. If more than 12 samples need to be analyzed at once, enhanced-multiplexing methods can 
be applied.  
Both isotopic labeling and isobaric tagging strategies have several advantages. For 
example, sample throughput increases directly in proportion to the number of samples that can 
be multiplexed.  Less experimental error is achieved as after the tags are introduced, therefore, 
all samples are subject to the same experimental errors in sample preparation. There are also 
practical advantages of reducing MS analysis time, labor, and costs. While there are many 
benefits to multiplexing, there are a few challenges as well. For example, inefficient labeling of 
proteins or peptides can complicate MS spectra and data analysis and lead to inaccurate relative 
protein quantitation. Some labeling reactions are pH and buffer specific76-77, 80 and if the reaction 
conditions are incorrect, undesirable side products may be produced77 and reduce the labeling 
efficiency. Other labeling methods require several iterations to achieve high labeling 
efficiencies71-72 which lengthens sample preparation time. To ensure that both peptides within a 
pair (or multiplets) are selected for MS analysis, peptide co-elution is necessary. Depending on 




the LC separation.81 This issue has been addressed by incorporating tags with fewer atoms of 2H 
and more atoms of 18O, 13C, and/or 15N. 29, 75, 81-82   Due to the fact that every peptide will appear 
as a doublet or triplet in the precursor m/z spectra, spectral complexity is increased. This may be 
problematic if one peak in the multiplet is selected more frequently for fragmentation as only 
information for that sample is obtained. Lastly, reagent costs for multiplexing can vary from a 
few dollars to >$500 per experiment. Furthermore, isobaric tagging reagents mostly require the 
use of high-resolution instruments to distinguish between reporter ions.   
1.3 ENHANCED MULTIPLEXING TECHNIQUES 
Multiplexing with isotopic and/or isobaric tagging strategies allow for many samples to 
be analyzed at once, however limitations are present. If more than 12 samples need to be 
analyzed, enhanced-multiplexing tagging methods can be employed.73-74, 80, 83-88 One strategy 
used in our laboratory is combined precursor isotopic labeling and isobaric tagging (cPILOT). 
1.3.1 Combined Precursor Isotopic Labeling and Isobaric Tagging (cPILOT) 
Our laboratory developed cPILOT, which labels the N-terminus of peptides with heavy 
isotopes and lysine residues with isobaric tags.83 Initially, this method was applied to study the 
post-translational modification (PTM) 3-nitrotyrosine (3NT) in which N-termini and lysine 
residues were blocked with light and heavy acetyl groups. 3NT modified peptides were then 




tagged. cPILOT was shown to selectively label the N-terminus and lysine residues and was able 
to identify and quantify peptides; however, issues with co-isolation and quantitation were evident 
due to the use of a 2H3 acetylation heavy tag and missing reporter ion information. In order to 
maximize the number of peptides that are quantified and have signal in reporter ion channels and 
broaden the types of analyses that can be studied, different sample preparation strategies and data 
acquisition methods were developed. 
The first change made was related to the isotopic labeling strategy used. This labeling 
method was changed to dimethylation (Figure 1.5). This reaction was performed at low pH (pH 
~2.5-3), to selectively label the N-terminus of peptides. In addition, using dimethylation reduced 
co-isolation between peptide pairs. To improve quantification, MS3 acquisition with a top-ion or 
selective-y1-ion method was employed. This helped reduce reporter ion interference and improve 
quantitative accuracy of cPILOT.80 Changes made in cPILOT reactions and data acquisition 
were applied to study the brain proteome of an Alzheimer’s disease mouse model (APP/PS-1) 
and showed that cPILOT successfully labeled peptides with high efficiencies (i.e. 98%) and 









To study cysteine, the amino acid selective approach cysteine cPILOT (cyscPILOT) was 
developed.85 As cysteine containing peptides are low (~14%) in abundance, sample preparation 
included cysteine enrichment. Labeling by cPILOT was adjusted by performing on-resin 
dimethylation and using iodo-TMT tagging reagents. Results showed that labeling with 
cyscPILOT was successful and that changes in the liver proteomes of APP/PS-1 mice were able 
to be detected.  With the techniques learned from cyscPILOT, OxcyscPILOT89-90 was developed. 
This method uses similar methodology as cyscPILOT, but was altered to select specific oxidative 
cysteine modifications. To prepare S-nitrosylated samples, free thiols were blocked, SNO-
containing peptides were enriched, and on-resin labeling by cPILOT was performed. This 
method was used to study SNO modifications in APP/PS-1 brain samples and showed that 1) 
OxcyscPILOT successfully enriched SNO containing peptides and 2) endogenous SNO levels in 
AD were able to be quantified.  
cPILOT has also been employed to study liver tissues84 and more recently, brain, heart, 
and liver tissues (Chapter 4) from 14-month-old APP/PS-1 mice. In the study of the liver 
proteome, samples from AD and WT mice were labeled by cPILOT and analyzed by using a 
two-tiered data-dependent acquisition (DDA) method. This method was employed to increase 
overall peptide identifications and to identify and quantify a wider dynamic range of peptides.  
The development and improvements of cPILOT labeling and analysis methods show the 
versatility and flexibility of using this method. Recently, cPILOT multiplexing capabilities have 
been increased to 24 samples by using DiLeu 12-plex.91 DiLeu tags can be synthesized in the 
laboratory, therefore using these tags can dramatically decrease sample preparation costs. This 





1.4 OVERVIEW OF DISSERTATION 
 
This body of work is a compilation of projects that employ quantitative proteomics 
techniques to study aging, infection, and Alzheimer’s disease in both worm and mouse models, 
along with post-mortem human tissues. Host – response of young- and aging-adult 
Caenorhabditis elegans (C. elegans) exposed to the opportunistic pathogen Pseudomonas 
aeruginosa strain PA01 are studied (Chapter 2), providing novel insights into the relationship 
between age and immunosenescence in metazoans. Improvements in Orbitrap instrumentation 
are applied to same C. elegans samples (Chapter 3) to better understand the Elite MS and gain 
additional information about the effects of aging on the molecular mechanisms involved in 
response to pathogen exposure. To study larger sample-cohorts (e.g. 36 samples), the enhanced 
multiplexing strategy combined precursor labeling and isobaric tagging (cPILOT) is applied. 
This technique is especially helpful when studying multiple tissues and biological replicates in 
models of disease, such as Alzheimer’s disease. Specifically, cPILOT optimization on an 
Orbitrap Lumos platform and its application to brain, heart, and liver proteomes of an 
Alzheimer’s disease mouse model (Chapter 4) and human post-mortem (Chapter 5) tissues are 




2.0 PROTEOMICS ANALYSIS OF VIRULENCE-RELATED FACTORS IN YOUNG 
AND AGING C. ELEGANS EXPOSED TO PSEUDOMONAS AERUGINOSA PA01- 
PART 1* 
(*please note, contents of this Chapter are based off of the following publication: “King, C.D; Singh, D.; Holden, K.; Govan, A.B.; Keith, S.A.; 
Ghazi, A., Robinson, R.A.S. Journal of Proteomics, 2018, https://doi.org/10.1016/j.jprot.2018.04.006”) 1 
2.1 INTRODUCTION 
 Aging is characterized by the progressive accumulation of a variety of physiological 
impairments. One of the more challenging and early age-associated declines is 
immunosenescence- the gradual deterioration of the immune system with increasing age. 
Conserved across a wide evolutionary scale, immunosenescence contributes substantially to the 
increased morbidity and mortality of elderly populations.92-93 Starting in middle age, both 
vertebrates and invertebrates exhibit defects in nearly every cell type and process required for 
immune capability. Given the rapidly aging global population,94 there is an urgency to 
understand the cellular and molecular mechanisms underlying immunosenescence. 
The major consequence of immunosenescence is an increased susceptibility to infectious 




Pseudomonas aeruginosa is a well-known pathogen responsible for a significant number of 
hospital-acquired infections96 especially in individuals suffering from cystic fibrosis,97 cancer,98 
AIDS,99-100 or other immune-suppressing illnesses. This is partly due to the microbe’s propensity 
for colonizing inserted medical care devices.101 P. aeruginosa infection is accompanied by 
biofilm formation and exotoxin secretion, and can result in sepsis- a potentially fatal systemic 
inflammatory response. The rapid evolution of P. aeruginosa and its growing antibiotic 
resistance makes investigations of the versatile strains important, especially with respect to 
immunosenescence. Better understanding the molecular dynamics of host-pathogen interactions 
in this context could facilitate the development of more effective antibiotics, or pharmaceutical 
enhancers of intrinsic immune function in high-risk patient groups. 
The nematode Caenorhabditis elegans102 is subject to infection by various human 
bacterial pathogens, many of which enact infectious processes that are quite comparable, at the 
cellular level, to their modes of pathogenesis in humans.8 Indeed, the capacity of multiple P. 
aeruginosa strains to rapidly kill C. elegans populations through both biofilm-like-colonization 
mediated infections and via secreted exotoxins has been described extensively.9-11 Additionally, 
while lacking an adaptive immune system, the critical regulatory elements known to coordinate 
innate immunity in C. elegans are highly conserved in vertebrates, such as the p38 mitogen-
activated protein kinase (MAPK), transforming growth factor (TGF)-β, and DAF-2 insulin/IGF1 
signaling pathways.12-14 Further, C. elegans’ infection-resistance mechanisms undergo 
immunosenescent decline with age in a manner dependent on deteriorating p38 MAPK 
function.15 Collectively, the ability to recapitulate infection phenotypes for numerous 




genetic manipulations have made the worm an ideal model for examination of innate immune 
responses to pathogen. 
Given the fully sequenced and curated C. elegans genome,102 the worm offers a unique 
capacity for large-scale explorations of molecular factors either induced or repressed by 
infection. Full-genome microarrays and RNA-sequencing have been implemented to survey 
genes that are either up- or down-regulated at the transcriptional level in response to P. 
aeruginosa, Drechmeria coniospora, Staphylococcus aureus, Serratia marcescens, and Yersinia 
pestis and others.9, 14, 18-21, 103 These efforts have provided considerable insight into common 
pathogen-specific immune events. However, despite recent technical advances in performing 
proteomics analysis with C. elegans,104-107 to-date studies profiling protein-level expression 
changes in pathogen-challenged worms have been limited22-26, 107-109 and studies comparing the 
proteomic alterations observed in Day 1 vs. Day 5 animals facing pathogenic challenges have 
been not been reported. 
In the present study, we employed two independent quantitative proteomics approaches, 
Tandem Mass Tag (TMT6) isobaric tagging and reductive dimethylation chemical labeling to 
profile the protein-level changes experienced by Day 1 and Day 5 C. elegans exposed to 
pathogenic P. aeruginosa strain PA01 (henceforth labeled ‘P. aeruginosa PA01’) relative to C. 
elegans fed on the laboratory diet of Escherichia coli strain OP50 (henceforth labeled ‘E. coli 
OP50’). Overall, we identified 55 unique proteins that exhibited significantly altered levels in 
Day 1 or Day 5 worms upon pathogen exposure of which ten were identified at both ages. The 
proteins common between Day 1 and Day 5 worms’ response to pathogen included cytoskeletal 
proteins involved in locomotion as well as enrichment of reproductive functions. In Day 5 




accordance with our proteomic predictions, we observed that PA01 exposure increased protein 
carbonylation suggesting sustained oxidative stress after pathogen exposure. Additionally, we 
evaluated the lifespan of mutants for the protein, UNC-60, whose levels were altered by both age 
and pathogen exposure and found that mutants of unc-60 have reduced lifespan. Overall, our data 
provide novel insights into the cellular responses mounted by metazoans when exposed to the 
clinically relevant pathogen P. aeruginosa, and into the molecular changes that occur at the 
intersection of aging and immunity. 
2.2 EXPERIMENTAL PROCEDURES 
2.2.1 Nematode and Bacterial Culture 
C. elegans N2 Bristol wild type worms were maintained via standard laboratory 
techniques on nematode growth medium (NGM) plates seeded with Escherichia coli OP50, the 
normal laboratory diet.110 P. aeruginosa PA01–seeded pathogenicity–assay plates were 
generated as described previously for P. aeruginosa PA14 ″slow killing″ (SK) assays.111 Briefly, 
~5 mL liquid LB was inoculated from an individual PA01 colony and grown 8 – 16 h at 37 oC 
with shaking. Approximately 75 μL liquid culture was then seeded to SK plates,111-112 which 





2.2.2 Pathogenicity Assays 
Synchronized C. elegans populations of wild-type strain, N2, were obtained by isolating 
eggs via sodium hypochlorite treatment and allowing hatching overnight in M9 buffer (0.09 M 
NaCl, 0.04 M Na2HPO4, 0.02 M KH2PO4) at 20 oC.113 The resultant L1 larvae were then 
transferred to standard E. coli OP50–seeded NGM plates and incubated at 20 oC until Day 1 
adulthood. In order to evaluate pathogen resistance in Day 1 animals, one subset of worms were 
transferred to P. aeruginosa PA01–seeded SK plates on Day 1 of adulthood (~48 h post-L1 
incubation), while the control group remained on E. coli OP50–seeded NGM plates for the 
duration of the assay. Experimental and control subpopulations consisted of 60-100 individuals 
evenly distributed over five plates (15 – 20 worms/plate). To examine the pathogen resistance of 
Day 5 worms, synchronized populations were maintained on E. coli OP50–seeded NGM plates 
until Day 5 of adulthood before being distributed to P. aeruginosa PA01 plates or control E. coli 
OP50 plates, as was done for Day 1 animals. All worms were transferred to fresh plates every 
other day through the reproductive span to avoid both overcrowding and confusion between the 
study population and its progeny. Assay plates were incubated at 20 oC and scored for survival 
daily. Worms were considered dead upon failure to respond to repeated prodding with a platinum 
wire pick. Data reflecting worms that crawled off the media, exploded, bagged, or became 
contaminated were censored. The resulting survival data were used to generate Kaplan Meier 
curves with OASIS (Online Application of Survival Analysis),114 and P values were calculated 
via log rank (Mantel Cox method) test with the same software.114 Lifespan assays of the unc-60 
mutant strains, CB77 {unc-60(e677)}, ON19 {unc-60(su158)} and N2 controls were conducted 




2.2.3 Sample Preparation for Proteomics Analysis 
Sodium hypochlorite-mediated, L1–synchronized N2 worm populations were obtained in 
large numbers and reared to early adulthood on E. coli OP50–seeded NGM at 20 oC, (~80,000 – 
100,000 total worms). To examine the proteome of Day 1 adults challenged with P. aeruginosa, 
one group of ~20,000 worms was transferred to P. aeruginosa PA01–seeded SK plates (or 
control E. coli OP50–seeded NGM plates) on Day 1 of adulthood and maintained at 20 oC for 18 
h before harvesting. For Day 5 pathogen-exposure studies, worms were transferred to E. coli 
OP50–seeded NGM plates as described above, and maintained on the same food until Day 5 of 
adulthood (transferring to fresh plates every other day to avoid progeny contamination). On Day 
5, half the worms were transferred to P. aeruginosa PA01–seeded SK plates (the other control 
half to E. coli OP50–seeded NGM plates) and maintained at 20 oC for 18 h before harvesting 
both groups. Parents were separated from eggs and progeny during transfers by serially washing 
adults off the plates with M9 and then allowing the adults to settle by gravity. At their respective 
time points, worms were floated off plates with M9 buffer110 and washed two times to remove 
extraneous bacteria and obtain sample pellets. Two independent biological replicates were 
collected for the proteomic studies from each age group and bacterial exposure. 
2.2.4 Protein Extraction 
Worms were harvested, washed with M9 buffer to remove bacteria, and centrifuged to 
obtain a pellet. Pellets were re-suspended in Reassembly (RAB) buffer (0.1 M MES, 1 mM 




Protease Inhibitor (Roche Applied Science). Protein homogenate was sonicated for 10 s, 
followed by 50 s on ice, incubated for 10 min on ice and centrifuged at 14000 g. The amount of 
protein was determined by BCA assay (Thermo Scientific). A pooled sample (Sample #5) 
containing equimolar ratios of Day 1 E. coli OP50 (Sample #1) and P. aeruginosa PA01 (Sample 
#2) and Day 5 E. coli OP50 (Sample #3) and P. aeruginosa PA01 (Sample #4) samples, was also 
prepared. 
2.2.5 Protein Digestion 
Protein was purified using acetone precipitation and quantified by BCA assay. Protein 
(~80 – 100 µg) was denatured with an extraction buffer (0.2 M Tris, 8 M urea, 10 mM CaCl2, pH 
8.0), reduced with 1:40 molar excess of dithiothreitol (DTT) for 2 h at 37 oC, and then alkylated 
with 1:80 molar excess of iodoacetamide (IAM) for 2 h on ice. The alkylation reaction was 
quenched by adding 1:40 molar excess of cysteine and the mixture was incubated at room 
temperature for 30 min. Tris buffer (0.2 M Tris, 10 mM CaCl2, pH 8.0) was added to dilute the 
urea concentration to 2 M. Each sample was incubated with bovine TPCK-treated trypsin 
(Sigma–Aldrich) at 50:1 substrate/enzyme ratio for 24 h at 37 ºC. 
2.2.6 TMT Labeling 
Digested samples were desalted with an HLB cartridge and dried by centrifugal 
evaporation. Each sample was labeled with a TMT6-plex reagent following the manufacturer’s 




with 41 µL of acetonitrile, and transferred to peptide samples reconstituted in triethylammonium 
bicarbonate (TEAB) buffer. After 1 h of incubation (~25 oC), the reaction was quenched using 
5% hydroxylamine. Equimolar amounts of samples were combined such that reagents that 
generate reporter ions at m/z 126:127:128:129:130 correspond to D1 OP50, D1 PA01, D5 OP50, 
D5 PA01, and the pooled sample, respectively. 
2.2.7 Dimethylation Labeling 
Peptides (~50 μg) were reconstituted in 100 mM TEAB buffer (pH 8.5).  The following 
solutions were added to E. coli OP50 samples for light (-CH3)2 labeling and to P. aeruginosa 
PA01 samples for heavy (-13C2H3)2 labeling: 4% formaldehyde (16 μL) and 0.6 M sodium 
cyanoborohydride (16 μL) (Sigma–Aldrich) or 4% 13C, D2 – formaldehyde (16 μL) and 0.6 M 
sodium cyanoborodeuteride (16 μL) (Sigma–Aldrich), respectively. Samples were vortexed for 
10 min, quenched with 1% ammonia, and acidified with 5% formic acid. Samples were then 
desalted with an HLB cartridge, dried by centrifugal evaporation, and stored in the – 80 oC 
freezer until further analysis. 
2.2.8 Strong Cation Exchange (SCX) Fractionation 
SCX fractionation was performed on a PolySulfoethyl A 100 mm x 2.1 mm, 5µm, 200 Å 
column (The Nest Group, Inc.) with buffers as follows: mobile phase A was 5 mM 
monopotassium phosphate (25% v/v acetonitrile, pH 3.0), and mobile phase B was 5 mM 




TMT6– labeled samples were re-suspended in 200 µL of mobile phase A and injected onto the 
column. The gradient was as follows: 0 – 5 min, 0% B; 5 – 45 min, 0 – 40% B; 45 – 90 min, 40 – 
80% B; 90 – 100 min, 80 – 100% B; 100 – 110 min, 100% B; 110 – 121 min, 0% B. Eluent was 
collected every minute and combined into 20 fractions. Each fraction was desalted using Supel-
Tips C18 micropipette tips (Sigma – Aldrich). Fractions were solubilized in 50 µL and filtered 
with a 0.45 μm filter (Thermo Fisher Scientific).   
2.2.9 LC – MS Analyses 
Online desalting and reversed-phase chromatography was performed with a Nano liquid 
chromatography (LC) system equipped with an autosampler (Eksigent). Mobile phases A and B 
used for reversed phase (RP)-LC separation of peptides were 3% (v/v) acetonitrile with 0.1% 
formic acid and 100% acetonitrile with 0.1% formic acid, respectively. SCX fractions (10 μL) 
were loaded onto a trapping column (100 µm i.d. x 2 cm), which was packed in house with C18 
(3 µm, 200 Å) stationary phase material (Michrom Bioresource Inc,) at 3 μL/min in 3% mobile 
phase B for 3 min. After desalting, the sample was loaded onto an analytical column (75 µm i.d. 
x 13.2 cm) which was packed in-house with C18 (3 µm, 100 Å) stationary phase material 
(Michrom Bioresource Inc). The gradient was as follows: 0 – 7 min, 10% mobile phase B; 7 – 67 
min, 10 – 30% B; 67 – 75 min, 30 – 60% B; 75 – 77 min, 60 – 90% B; 77 – 82 min, 90% B; 82 – 
83 min, 90 – 10% B; 83 – 95 min, 10% B. The LC eluent was analyzed with positive mode 
nanoflow electrospray using a LTQ Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific). Data-dependent acquisition parameters were as follows: the MS survey scan in the 




and fragmented with collision-induced dissociation (CID) in the LTQ (normalized collision 
energy of 35%). Directly after each MS/MS scan, the most intense fragment ion over the m/z 
range 200 – 1545 was selected for higher-energy collisional dissociation (HCD) triple staged 
mass spectrometry (MS3). The fragment isolation width was set to 4 m/z, the MS3 AGC was 3 x 
105, the normalized collision energy was 60%, the resolution was 7500 and the maximum ion 
time was 250 ms. HCD spectra were recorded in the Orbitrap. Each fraction was subject to 
duplicate injections.  
Dimethylated samples were analyzed by LC – MS/MS. Similar mobile phases, trapping 
and analytical column settings, and instrument settings were used to perform the analysis, except 
the analytical gradient was: 0 – 5 min, 10% mobile phase B; 5 – 40 min, 5 – 40% B; 40 – 90 min, 
15 – 25% B; 90 – 115 min, 25 – 30% B; 115 – 130 min, 30 – 60% B; 130 – 135 min, 60 – 80% 
B; 135 – 145 min, 80% B; 145 – 150 min, 80 – 10% B; 150 – 180 min, 10% B.  Data-dependent 
acquisition parameters: MS survey scan in the Orbitrap (300 – 1800 m/z) with 60000 resolution; 
the top fifteen most intense peaks were isolated and fragmented with CID in the LTQ 
(normalized collision energy of 35%). Each fraction was also subjected to duplicate injections 
(technical replicates). 
2.2.10 Data Analyses 
RAW files were analyzed with PD 1.4 software (Thermo Scientific). Spectra were used 
to obtain sequence information against the Uniprot C. elegans database (11/26/2013, 25673 
sequences). SEQUEST search parameters were as follows: two maximum trypsin miscleavages, 




were TMT six-plex/+229.163 Da (N-terminus, Lys) and carbamidomethyl modification/+57.021 
Da (Cys); dynamic modification was oxidation modification/+15.995 Da (Met). Decoy database 
searching was employed to generate medium (p<0.05) and high (p<0.01) confidence peptide 
lists. All the peptides with medium and high confidence were used to identify and quantify 
proteins. To filter peptides, the following parameters were applied:  peptide confidence level of 
medium or high, peptide rank of 1, and peptide deviation of 10 ppm. Peptides with a PSM 
(peptide to spectral match) count of 1 (per technical replicate) were not considered for analysis. 
The reporter ions (i.e. m/z 126 – 130) were identified with the following parameters:  most 
confident centroid and 20 ppm for reporter ion mass tolerance. Furthermore, reporter ion values 
were normalized 126/130, 127/130, 128/130, and 129/130 and final ratio reporting given as 
127/126 and 129/128. Proteins belonging to multiple isoforms were grouped into a single 
accession number and final ratios were reported.  
A power analysis was performed using protein ratios from TMT6-plex data to generate an 
appropriate fold-change cutoff. Coefficient of variation (CV) values were calculated as 
previously explained for reporter ion ratios of proteins quantified in both biological replicates.115 
The mean CV value from both biological replicates was calculated and used as the total 
biological variation, Sb, (i.e. 0.36). The technical variation, St, was calculated for proteins 
quantified in at least one technical replicate of each biological replicate, and was 0.22. The 
power of the test and the significance level was set to 0.8 and 0.05, respectively. Filter criteria 
were applied to generate a list of proteins showing differential levels as follows: 1) proteins 
identified and quantified in at least one technical replicate and both biological replicates, 2) CV 




Data from the dimethylation experiment was treated by applying the following criteria: 1) 
proteins identified and quantified in both technical replicates and 2) fold-change cutoff 
dependent on p <0.05 such that ≥ 1.4 or ≤ 0.70. 
2.2.11  Measurement of Protein Carbonylation Levels  
Immunoblot assays were performed using one biological cohort of Day 1 and Day 5 C. 
elegans to measure oxidative stress in C. elegans exposed to P. aeruginosa PA01. Protein 
carbonylation (PCO) measurement was performed using Dot/Slot blot. Protein from samples 1 – 
4 (5 µL) were dissolved in 1× PBS, 12% SDS and derivatized with 20 mM 2,4-
dinitrophenylhydrazine (DNPH) for 20 min. The reactions were quenched using neutralization 
buffer and the samples were diluted using 1× PBS buffer to have a concentration of 1 ng/µL. 
Nitrocellulose membrane and filter paper (2) were briefly soaked in PBS buffer and the Dot/Slot 
blot apparatus was assembled. The membrane was rinsed with 200 µL of PBS, protein samples 
(250 ng) were loaded onto the Dot/Slot blot apparatus, and then the membrane was rinsed an 
additional time. The membrane was removed and samples were incubated in blocking buffer (3% 
w/v BSA in wash blot) for 90 min (room temperature). Primary antibody (anti – 2,4-
dinitrophenyl) was added with a dilution of 1:2000 and left to incubate overnight (4 oC). The 
following day, the membrane was brought up to room temperature for 30 min, then washed 4 
times with wash blot (5 min intervals). Secondary antibody (anti-rabbit IgG alkaline 
phosphatase) was added with the dilution factor 1:5000 with 20 mL wash blot and the membrane 
was incubated for 60 min (room temperature). The membrane was rinsed in wash blot (3 times, 5 




tetrazolium (NBT). The solution was allowed to incubate till blue spots appeared. Results were 
analyzed using Scion Image software. Six technical replicates were performed. 
2.3 RESULTS 
2.3.1 C. elegans Resilience to P. aeruginosa PA01 Declines with Increasing Age 
The reliability of our proteomics data first depended on a bona fide bacterial infectivity 
and pathogenicity C. elegans model. This confirmatory step was particularly critical given the 
non-traditional solid – SK – media platform required to generate large cohorts of C. elegans. 
Hence, we performed standard pathogenicity assays to assess the lethality of P. aeruginosa PA01 
on wild-type C. elegans and to directly compare the survivals of Day 1- and Day 5 animals 
challenged with this pathogen. Similar to P. aeruginosa PA1415, P. aeruginosa PA01 exposure 
resulted in a dramatic decrease in the lifespan of both age groups in comparison with E. coli 






Figure 2.1 Survival Curves of Exposed and Control C. elegans. The lifespans of Day 1 (D1) and Day 5 
(D5) adult control and exposed D1 and D5 C. elegans were compared to survival on the standard laboratory diet of 
E. coli OP50. N2 (E. coli OP50) D1 OP50 (green; m= 18.7 ± 0.4, n= 39/44), D1 PA01 (blue; m= 11.2 ± 0.6, n= 
41/49, P vs. N2 <0.001), N2, D5 OP50 orange; m= 21.9 ± 0.7, n= 36/46) D5 PA01 (yellow; m= 11.7 ± 0.7, n= 











C. elegans reared on E. coli OP50 and transferred to P. aeruginosa PA01 – seeded SK 
plates on Day 1 of adulthood had a mean lifespan of 11.2 ± 0.6 days vs. mean lifespan of 18.7 ± 
0.4 on E. coli OP50 while those transferred as Day 5 adults perished after 11.7 ± 0.7 days, vs. 
mean lifespan of 21.9 ± 0.7 on E. coli OP50. Upon pathogen exposure, Day 5 adults began to 
perish within 24 h while Day 1 adults maintained 100% survival for several days. Both Day 1 
and Day 5 adults’ survival were reduced in the presence of pathogen. In an independent trial, a 
29% reduction in the survival of Day 5 adults exposed to pathogen was observed (Appendix A 
Table A2.1). These data confirmed that P. aeruginosa PA01, similar to the PA14 strain of the 
same pathogen15, reduces C. elegans’ survival and the detrimental effects are stronger in Day 5 
adults than Day 1. It also shows that both Day 1 and Day 5 had initial differences in survivability 
upon exposure to pathogen. Therefore, proteome changes identified in this work are likely 
reflective of genuine C. elegans infection responses. 
2.3.2 Mapping the C. elegans Proteome upon P. aeruginosa PA01 Exposure 
In a recent report, Vigneshkumar et al. used two-dimensional difference in gel 
electrophoresis (2D-DIGE) to identify 19 proteins whose levels are altered upon PA01 infection 
in Day 1 worms.25  However, little is known about genome-level proteome changes that occur in 
worms following infection with bacterial pathogens, especially with respect to the influence of 
aging. To systematically address this, we applied a proteomics workflow that takes advantage of 
isobaric tagging to simultaneously assess changes in the C. elegans proteome upon exposure to 
P. aeruginosa PA01 in Day 1 of adulthood vs. Day 5 of adulthood worms (Figure 2.2, Full Mass 




aeruginosa PA01 at Day 1 or Day 5 and harvested 18 hours after P. aeruginosa PA01 exposure. 
This time-point was selected because it allowed a suitable exposure time to the pathogen to 
establish an infection-related proteome and, as is evident from the lifespan curves in Fig. 1, was 
a stage before large-scale death commenced. This ensured that the proteome responses measured 
were likely to be primarily related to immune responses and not mortality processes (e.g., 
apoptosis, degradation, etc.), and to give insight into immediate host responses to pathogen. As 
shown in Figure 2.2, proteins from each of the groups including a pooled sample were tryptically 
digested. Peptides were tagged with TMT6 reagents and analyzed by LC – MS/MS and MS3 as 
follows: Day 1 C. elegans fed on E. coli OP50 (m/z 126), Day 1 C. elegans exposed to P. 
aeruginosa PA01 (m/z 127), Day 5 C. elegans fed on E. coli OP50 (m/z 128), Day 5 C. elegans 
exposed to P. aeruginosa PA01 (m/z 129), and the pooled sample (m/z 130). MS3 was employed 
to help minimize ratio compression associated with reporter ion signals.80, 116-117 Biological and 
technical replication helped ensure we were observing reproducible changes.  
Example data from the proteomics workflow is shown in Figure 2.2. The peptide, 
N(TMT6)ANADIQQWK(TMT6) belongs to the myosin-4 protein and the MS and MS/MS 
spectra contain signal from samples for each of the four groups. After MS3 of the b4 fragment ion 
at m/z 601.49 is performed, reporter ions that track the sample origin for each group are detected. 
For this particular peptide, its relative abundance is higher in C. elegans exposed to P. 
aeruginosa PA01 relative to controls at both ages (i.e., D1 PA01/D1 OP50 = 3.12 and D5 
PA01/D5 OP50 = 1.34). In addition, it’s clear that myosin-4 has higher levels overall in Day 5 C. 





Figure 2.2 Proteomics Experiments and Mass Spectra of C. elegans Exposed to P. aeruginosa PA01.a) Proteomics 
workflow used to analyze C. elegans exposed to P. aeruginosa PA01. Representative b) MS, c) MS/MS and, d) MS3 
spectra from TMT6 labeled peptides is shown. The peptide sequence N(TMT6)ANADIQQWK(TMT6) belongs to 
myosin-4 and was selected at m/z 766.439 (SCX fraction 8, tr = 29.46 min), isolated, and fragmented. The fragments 
produced CID-MS/MS spectra. Next, the b4 ion at m/z 601.490 was isolated, selected, and fragmented, generating 
HCD-MS3 spectra.  A zoom – in at low m/z of this spectra is shown, displaying reporter ions for this fragment. An 
example mass spectrum from a pooled sample of light (m/z 648.856) and heavy (m/z 656.900) e) dimethylated 
labeled D1 OP50 and D1 PA01 samples, respectively, at tr =62.48 is also shown. The peptide pair corresponds to 




The spectra in Figure 2.2 are representative of the entire dataset, whereby ~1.6 x 106 
MS/MS spectra were acquired. These spectra led to the identification of 897 unique proteins 
(4248 peptides) using the conservative criteria of Peptide to Spectral Match (PSM) ≥2 combined 
from any two technical replicates (Appendix A Table A2.2). With less conservative filters 
(PSM>1 across the 4 technical replicates), 1015 unique proteins were identified (Appendix A 
Tables A2.2 and A2.3).  
2.3.3 Dimethylation Labeling Verifies TMT6-based Identification of Proteins Whose Levels are 
Altered in PA01 Infection  
We employed reductive dimethylation as a complementary means to measure protein 
expression (Figure 2.3)118 such that in a single analysis (see Experimental) Samples 1 vs. 2 (D1 
OP50 vs. D1 PA01) or Samples 3 vs. 4 (D5 OP50 vs. D5 PA01) were compared. Protein samples 











Figure 2.2 provides a sample MS spectrum of a dimethylated peptide pair with the light 
peak at m/z 648.856 and the heavy peak at m/z 656.900. These peaks have the sequence 
N(dimethyl)TSLFTNLESTK(dimethyl) and belong to myosin-4. Similar to the TMT6 data, this 
protein was expressed at higher levels (D1 PA01/D1 OP50 = 1.86 ± 0.00) after P. aeruginosa 
PA01 exposure compared to E. coli OP50 controls in Day 1 C. elegans. The combined 
dimethylation experiments resulted in the identification of 3125 peptides and 662 proteins 
(Appendix A Tables A2.4 and A2.5). Overall, from both TMT6 and dimethylation datasets, 1206 
unique C. elegans proteins were identified and 462 proteins were common (Figure 2.4a).   
 We compared the list of proteins with differential levels identified through TMT6 
labeling (Table 2.1) with those found to exhibit differential levels through the dimethylation 
approach. Eighteen proteins were common between these groups and their PA01/OP50 ratios are 
shown in Figure 3b. Overall, 13 of the 18 proteins (Figure 2.4b) shared similar changes between 
the two techniques (i.e., <25% coefficient of variation), enhancing our confidence in the list of 











Figure 2.4 Comparisons of Proteins from TMT6 and Dimethylated-Labeled Peptides. a) Venn diagram of proteins 
identified in TMT6 and dimethylation experiments and b) histogram plot of proteins exhibiting differential levels in 







2.3.4 Major Biological Pathways Influenced in C. elegans Proteome after Exposure to P. 
aeruginosa PA01 
We performed two gene ontology searches on the list of proteins with differential levels 
in Day 1 and Day 5 adult C. elegans using the STRING database platform (Figures 2.5 and 
2.6).119 Overall, the proteins whose levels changed in response to pathogen (independent of age) 
included many cytoskeletal and structural proteins mediating myofibril assembly as well as those 
involved in biological processes such as reproduction, locomotion, stress response, metabolism, 
protein translation, and development (Table 2.1, Appendix A Table A2.6).  
In Day 1 C. elegans in particular, significant association was observed with the biological 
process (Appendix A Table A2.7) generation of precursor metabolites and energy (P <0.05) 
whereas, in Day 5 C. elegans the most significant associations (Appendix A Table A2.8) were 
with protein folding and stress response, including the unfolded protein response (UPR) and 
endoplasmic reticulum stress response (UPRER). As C. elegans age, increased protein 
aggregation occurs and their ability to maintain protein homeostasis declines,107 and these 



















2.3.5 PA01 Exposure Elevated Protein Carbonylation in C. elegans  
Protein carbonyls are products of metal-catalyzed oxidation of amino acids that are 
irreversible, unlike reversible oxidative changes that can be transient. Hence, levels of protein 
carbonylation (PCO) are an indirect but reliable and permanent marker of oxidative stress. 
Additionally, PCO increases with age in worms as in many other species.120 Many pathogens, 
including P. aeruginosa, causes increased oxidative stress upon infection. But, whether these 
stress-responses are similarly affected in animals of different ages is not clear. To examine the 
permanent, oxidative consequences of PA01 infection in Day 1 and Day 5 C. elegans, we 
measured PCO levels in our samples using immunoblot assays (Figure 2.7). Relative to Day 1 C. 
elegans fed OP50, oxidized PCO levels in Day 1 C. elegans after pathogen exposure increases 
by 16% (P < 0.05). We observed, as previously noted, that aging caused higher PCO levels. In 
Day 5 C. elegans fed OP50 compared to Day 1 C. elegans, PCO levels were higher by 15% (P < 
0.05). However, pathogen exposure in Day 5 C. elegans did not result in any further increase in 
PCO levels. Thus, pathogen infection appears to enhance oxidative damage to the animals’ 






Figure 2.7 Comparisons of Protein Carbonylation (PCO) Levels in Day 1 and Day 5 Adult C. elegans Exposed to P. 













2.3.6 unc-60 Mutants Have Reduced Lifespan 
In our analyses, one protein, UNC-60, exhibited differential levels both as a result of 
pathogen exposure as well as a function of age (Table 2.1, Appendix Table A2.9). UNC-60 
expression decreased with pathogen exposure in Day 1 C. elegans (0.54 ± 0.02 on comparing 
Day 1 OP50 vs. Day 1 PA01) whereas, in Day 5 adults its level was elevated upon pathogen 
exposure (1.50 ± 0.53). With age, UNC-60 expression increased substantially on E. coli OP50 
(2.85 ± 0.98 in Day 5 vs. Day 1 adults) and even more dramatically upon PA01 exposure (7.33 ± 
2.02 in Day 5 adults on PA01 vs. Day 1 adults on PA01). 
UNC-60 is an actin-polymerizing factor, cofilin, that is critical for numerous 
developmental steps as well as for normal locomotion in adults.121 Importantly, UNC-60 is 
required for C. elegans to avoid pathogenic bacteria. UNC-60 knockdown hastens mobility 
decline in aging animals and limits pathogen avoidance.122-123 Our data suggested that UNC-60 
confers locomotory ability under normal aging conditions, whereas, upon pathogen exposure, its 
levels may be elevated to facilitate avoidance behavior. We tested this by measuring the lifespan 
of two unc-60 mutant strains, CB677 {unc-60(e677)} and ON19 {unc-60(su158)}. Both mutants 
exhibited severe whole-body paralysis and sickness121 and were significantly shorter-lived 
compared to wild-type controls. CB677 exhibited a mean lifespan of 7.0 ± 0.1 days, whereas, for 
ON19 lived for 7.3 ± 0.2, as compared to the 18.6 ± 0.2 days mean lifespan of the control 





Figure 2.8 Survival Curves of Day 1 Adult unc-60 Mutants and Control C. elegans. Mean lifespans of two loss-of-
function unc-60 mutants compared to wild-type, N2, C. elegans grown on standard laboratory diet of E. coli OP50 
throughout their lives were measured at 20oC. (blue; m= 18.9 ± 0.1, n= 80/116), ON19 {unc-60(su158)} (green; m= 
5.9 ± 0.1, n= 38/43, P vs. N2 <0.0001), CB677 {unc-60(e677)} (yellow; m= 7.8 ± 0.1, n= 104/119, P vs. N2 




The dramatic 60% lifespan reduction seen on normal food itself precluded survival 
analysis upon pathogen exposure. These observations are in keeping with our proteomics data 
and other reports that indicate that mutations in unc-60 reduce the lifespan of WT adult C. 
elegans. 
2.3.7 Comparing C. elegans Host Response when Exposed to P. aeruginosa PA01 and Other 
Pathogens 
Several reports have examined the gene- and –protein-expression changes in C. elegans 
as a result of infection by a variety of pathogens.9, 14, 18, 20-23, 109 These efforts have primarily 
focused on such changes at the transcriptional level. Proteomics has been used to investigate 
host-pathogen response for the Gram-positive human pathogen Staphylococcus aureus (S. 
aureus), a pathogenic Escherichia strain, E. coli LF8222-23 and recently, P. aeruginosa PA01.25, 
103 Transcriptomic studies have also been performed on the canonical pathogenic P. aeruginosa 
strain PA14, a human clinical isolate.14, 18 We anticipated that there would have been higher 
overlap of our changes with those from the other P. aeruginosa PA01 study which examined 






Figure 2.9 Comparison of Differentially – Expressed genes/proteins from this Study to other Pathogenicity Studies. 
The bar graph shows the number of shared proteins/transcripts present at differential levels from P. aeruginosa 
PA01 and other pathogens. The quadrants represent categories of proteins with, a) higher levels in P. aeruginosa 
PA01 exposed C. elegans as well as the other pathogen(s), b) lower levels in P. aeruginosa PA01 and in the other 
pathogen(s), c) lower levels in P. aeruginosa PA01 in our study and higher levels in the other pathogen(s), d) and 




Two proteins (i.e. disorganized muscle protein and receptor of activated protein c kinase 
1) had consistent direction of change between both studies and showed higher differential levels 
(Figure 2.9a), whereas three proteins (i.e. elongation factor 2, fatty-acid binding protein homolog 
6, and pud 1.1) had an opposite direction of change (Figure 2.9d). Interestingly, the study with 
the highest degree of overlap was with gene-expression changes reported when C. elegans was 
exposed to S. aureus22 (P < 4.89 x 10-20). We next compared our list of proteins exhibiting 
differential levels in our study with the proteins identified in other proteomic analyses of C. 
elegans exposed to various types of pathogens (i.e. Gram-negative or Gram-positive bacteria or 
fungi) (Figure 2.9) 9, 14, 20-23, 25, 109 We found that eighteen proteins whose levels were elevated 
after pathogen exposure in our study (Figure 2.9a) and six whose levels were diminished (Figure 
2.9b), were also found to exhibit similar changes in one or more of the other studies. Only three 
proteins’ levels were reduced upon PA01 exposure in our study but showed higher levels upon 
pathogen attack in other reports (Figure 2.9c). These results are promising and suggested that 
some responses to infection are not pathogen specific. The highest degree of overlap (i.e. 27 
unique proteins) occurred however, for proteins elevated in the presence of PA01 in our study 
but lowered levels in the presence of other pathogens (Figure 2.9d). For example, 11 proteins had 
higher levels after P. aeruginosa PA01 exposure in our study but were reduced upon S. aureus 
infection22 suggesting that worms mount pathogen-specific responses that may involve up- or 
down-regulation of the same protein dependent upon the pathogen involved. These comparisons 







Previously, we have demonstrated that age influences the acute response to infection in 
elderly individuals suffering from community-acquired pneumonia that eventually develop 
severe sepsis.115 The human proteome has dynamic changes in response to these infections and 
the changes are age-related, mostly involving mechanisms related to lipid metabolism, 
inflammation, and acute-phase response.115 Despite the considerable differences in size, number 
of cells, and inherent complexity of the immune system, C. elegans has become a valuable model 
to study host-response to pathogens, especially to understand changes in innate immunity.124-126 
P. aeruginosa PA01 is a slow killing, Gram-negative bacterial strain implicated in human 
infections such as sepsis and pneumonia.127 Our proteomic studies measure the influence of 
aging on C. elegans exposed to P. aeruginosa strain PA01 using shotgun quantitative proteomics 
techniques. We aged C. elegans to Day 1 or day 5 in adulthood, exposed them to pathogen, and 
then harvested C. elegans at 18 hours. The time-point of 18 h was selected to maximize 
observance of changes related to infection.  Minimal media was used to introduce P. aeruginosa 
PA01 to C. elegans; this “slow-killing” assay leads to the accumulation of pathogen in the 
intestine through quorum sensing.128-130 Hydrogen cyanide is released from P. aeruginosa PA01, 
paralyzes C. elegans, and leads to lethal toxicity.128, 131 Herein, survivorship of C. elegans fed on 
NGM containing P. aeruginosa PA01 was significantly lower (i.e., LT50 = ~7-10 days compared 
to 18-20 days) than control C. elegans fed on E. coli OP50 media which is generally consistent 
with other studies.17, 132 However, worms in our study survived longer on P. aeruginosa PA01 
compared to previous reports.17, 132 These differences in survivability could be directly related to 




every other day. Initial mortality of C. elegans exposed to P. aeruginosa PA01 differs by several 
days for Day 1 and Day 5 C. elegans. Day 1 C. elegans have a lag time of several days prior to 
large percentages of the population dying whereas Day 5 C. elegans began to die more 
immediately upon P. aeruginosa PA01 exposure. This substantiates previous evidences that age 
diminishes C. elegans’ ability to effectively fight off the pathogen attack. However, after this 
period pathogen exposure does not have a long-term effect on the aging of C. elegans, as in our 
experiments Day 1 and Day 5 C. elegans exposed to P. aeruginosa PA01 have similar lifespans. 
This is likely due to differences in the innate response of young C. elegans. 
2.4.1 Pathogen-induced Proteomic Changes in Day 1 and Day 5 Adults are Overlapping but 
Distinct 
As C. elegans age, several proteomic and physiological changes occur, including 
structural disintegration,107 protein aggregation,107 and immunosenescence. In order to determine 
how aging influences the response to infection, we exposed Day 1 and Day 5 adult C. elegans to 
P. aeruginosa PA01 for 18 hours and examined their proteomes. We observed that there are 
general responses to infection that are not age-specific however, a few biological pathways are 
unique to a given age (Figure 2.10).   
The proteome of Day 1 C. elegans exposed to P. aeruginosa PA01 is notably enriched 
for developmental and reproduction functions (Appendix A Table A2.7). This is intuitive as Day 
1 C. elegans are completing larval stage 4 development and commencing egg laying. 
Cytoskeletal proteins and locomotion were significantly represented in both Day 1 and Day 5 C. 




the importance of pathogen-avoidance behavior for immunological defense in worms during 
both young and middle-ages.  
In Day 5 C. elegans, protein folding/unfolding and stress response pathways such as UPR 
and UPRER were significantly enriched along with metabolic functions. Upon pathogen 
exposure, Day 5 adult C. elegans elicit an elevated stress response to infection that is not 
observed in C. elegans on OP50. Specifically, we observe elevated levels of heat shock proteins 
(HSPs) after PA01 exposure. HSPs are chaperones that assist in protein folding,133 removal of 
improperly folded proteins,134 and stress response. Activation of HSPs after pathogen exposure 
and in aging is evolutionarily conserved, including in worms135 and is known to occur in other 
stressful conditions such as oxidative stress136-137 and after the onset of inflammatory diseases.138-
140 The combination of proteins being produced in response to stress and that are involved in 
metabolism, show a concerted effort from Day 5 C. elegans to counter the effects of pathogen – 






Figure 2.10 Scheme of Day 1 and Day 5 C. elegans’ Response to P. aeruginosa PA01 Exposure.  Day 1 (black) and 
Day 5 (orange) C. elegans were exposed to P. aeruginosa PA01, resulting in general and age-specific changes. Day 
1 adult C. elegans (grey arrows) had an increase in the generation of metabolic precursors and energy while Day 5 
adult C. elegans (green arrows) had significant changes related to protein metabolism and protein folding/unfolding. 
Both age groups had changes related to development, reproduction, locomotion, and structure. The loss of actin-
polymerizing protein, UNC-60, reduces C. elegans lifespan and antioxidants MSRA-1 and PRDX-3 reduce 








2.4.2 Mutations in unc-60 Reduce Lifespan 
Both myofiber structural integrity as well as locomotive ability decline with aging in 
worms as in humans.141 Interestingly, one proteins whose levels were altered by both age and 
pathogen exposure, though oppositely, was the cytoskeletal protein, UNC-60. UNC-60 is an 
actin-binding structural protein that mediates actin filament depolarization and is expressed in 
two, tissue-specific isoforms. Since UNC-60 was present at differential levels in both Day 1 and 
Day 5 aged C. elegans exposed to P. aeruginosa PA01 (see Results section above), we were 
interested in how the loss-of-function and protein expression of unc-60 may alter C. elegans’ 
lifespan. Survival curves of mutants CB677 {unc-60(e677)} and ON19 {unc-60(su158)} 
unveiled significant decreases in C. elegans’ lifespan, in comparison to the lifespan of control C. 
elegans. Interestingly, the lifespans of both mutants were similar, even though ON19 is 
considered to be the more severe mutant.121 Since UNC-60 is necessary for proper actin 
assembly in myofibrils,121, 142 the absence of this protein decreases C. elegans’ mobility and 
ability to obtain food, thus causing a premature death. Indeed, the mutants exhibited such a 
dramatic lifespan shortening under normal conditions that it precluded examining their survival 
in the presence of PA01. It can be inferred that upon pathogen exposure, similar or even more 
severe results would be yielded, as C. elegans would be unable to avoid the pathogen. 
2.4.3 P. aeruginosa PA01 Exposure Causes Elevated Carbonylation of Worm Proteome 
The presence of reactive oxygen and nitrogen species, and hence oxidative stress, is 




help protect against toxic species elicited from defense mechanisms and from the pathogen 
directly.144-145 In this study, antioxidant proteins peroxiredoxin-3 (PRDX-3) and methionine 
sulfoxide reductase 1 (MSRA-1) were elevated in Day 5 C. elegans exposed to P. aeruginosa 
PA01 and between Day 1 and Day 5 C. elegans, respectively. Elevation of PRDX-3 suggests 
activation of antioxidant pathways in response to oxidative stress (Table 2.1, Figure 2.8). 
MSRA-1 levels have been shown to decrease with aging in wild-type C. elegans146, however, our 
results show higher levels of this protein after pathogen exposure (Table 2.1). This change is 
supportive of an environment where C. elegans is warding off reactive oxygen and nitrogen 
species through an increased antioxidant response. Elevated levels of protein carbonyls (an 
indirect marker of oxidative stress) in Day 1 C. elegans upon pathogen exposure were observed 
in this study, very much consistent with the idea that ROS/RNS increases due to P. aeruginosa 
PA01.  
Inflammatory processes, antimicrobial activity, and innate immune responses to toxins 
lead to excess production of reactive oxygen and nitrogen species. However, in Day 5 C. elegans 
the exposure to pathogen did not result in any enhanced levels of oxidative stress. This 
observation suggests that by Day 5, worms were already experience increased oxidative stress 
which is not further exacerbated by PA01 infection (Figure 2.11).  
2.5 CONCLUSIONS 
This study provides new and significant insights into how the proteome of C. elegans 




significant alterations in metabolism, development, reproduction, stress response, protein 
folding/unfolding, and locomotion pathways. Many of these pathway changes are not unique to 
P. aeruginosa PA01 and are observed at the transcript or protein level when C. elegans are 
exposed to other Gram-negative and Gram-positive pathogens. However, we were able to 
observe a number of proteins that appear to have P. aeruginosa PA01-pathogen specific changes. 
Additionally, it is clear that the specific pathways that are activated in the proteome in response 
to pathogen depend on the age of the worms. Day 1 C. elegans have general alterations and do 
not have the confounding effects of aging that can limit their response to the pathogen. Initial 
survivability of Day 1 C. elegans is maintained for a longer period compared to Day 5 C. elegans 
prior to death after P. aeruginosa PA01 exposure. It will be very interesting to determine if these 
and other virulence-related factors identified in our study can be modulated to extend 





3.0 PROTEOMICS ANALYSIS OF VIRULENCE-RELATED FACTORS IN YOUNG 
AND AGING C. ELEGANS EXPOSED TO PSEUDOMONAS AERUGINOSA PA01- 
PART 2* 
(*please note, contents of this Chapter are related to the following publication: “King, C.D; Singh, D.; Holden, K.; Govan, A.B.; Keith, S.A.; 
Ghazi, A., Robinson, R.A.S. Data in Brief, 2016)147 
3.1 INTRODUCTION 
In Chapter 2, young and aging C. elegans were exposed to an opportunistic pathogen, P. 
aeruginosa PA01 to understand how aging influenced the response of C. elegans to infection. 
These experiments were performed on an LTQ Orbitrap Velos mass spectrometer, which offered 
high resolution, fast scan rates, and improved fragmentation spectra compared to other state-of-
the-art MS instruments.148 However, only ~1,000 proteins were identified with the use of this 
instrument in our proteomics platform. The LTQ Orbitrap Velos was upgraded to an Orbitrap 
Elite mass spectrometer and C. elegans samples were re-analyzed in order to take advantage of 
instrumental improvements. The Elite was improved from the LTQ Orbitrap Velos by including 
a neutral blocker, enhanced fourier transform (eFT) technology, and a smaller size Orbitrap. 




speeds to 250 ms (Orbitrap) and ~100 ms (ion trap).  Samples were prepared in a similar fashion 
as in Chapter 2, except only one biological cohort was applied. Protein from young and aging C. 
elegans exposed to P. aeruginosa PA01 and aged-matched controls were digested using trypsin. 
Peptides were labeled with TMT6-plex isobaric reagents and fractionated off-line with SCX. 
Fractions were analyzed by LC – MS/MS and MS3 and RAW files were searched using PD.  
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Protein Digestion 
Protein was purified using acetone precipitation and the amount of protein was re-
determined with BCA assay. Protein (~80 – 100 µg) was denatured with an extraction buffer (0.2 
M Tris, 8 M urea, 10 mM CaCl2, pH 8.0), reduced with 1:40 molar excess of dithiothreitol 
(DTT) for 2 h at 37 oC, and then alkylated with 1:80 molar excess of iodoacetamide (IAM) for   
2 h on ice. The alkylation reaction was quenched by adding 1:40 molar excess of cysteine and 
the mixture was incubated at room temperature for 30 min. Tris buffer (0.2 M Tris, 10 mM 
CaCl2, pH 8.0) was added to dilute the urea concentration to 2 M. Each sample was incubated 





3.2.2 TMT Labeling 
Digested samples were desalted with an HLB cartridge and dried by centrifugal 
evaporation. Each sample was labeled with a TMT6-plex reagent following the manufacturer’s 
protocol (Thermo Scientific). TMT6 reagents were equilibrated to room temperature, solubilized 
with 41 µL of acetonitrile, and transferred to peptide samples reconstituted in triethylammonium 
bicarbonate (TEAB) buffer. After 1 h of incubation (~25 oC), the reaction was quenched using 
5% hydroxylamine. Equimolar amounts of samples were combined such that reagents that 
generate reporter ions at m/z 126:127:128:129:130 correspond to D1 OP50, D1 PA01, D5 OP50, 
D5 PA01, and the pooled sample, respectively. 
3.2.3 Offline SCX Fractionation 
SCX fractionation was performed on a PolySulfoethyl A 100 mm x 2.1 mm, 5µm, 200 Å 
column (The Nest Group, Inc.) with buffers as follows: mobile phase A was 5 mM 
monopotassium phosphate (25% v/v acetonitrile, pH 3.0), and mobile phase B was 5 mM 
monopotassium phosphate, 350 mM potassium chloride (25% v/v acetonitrile, pH 3.0). Dried 
TMT6– labeled samples were re-suspended in 200 µL of mobile phase A and injected onto the 
column. The gradient was as follows: 0 – 5 min, 0% B; 5 – 45 min, 0 – 40% B; 45 – 90 min, 40 – 
80% B; 90 – 100 min, 80 – 100% B; 100 – 110 min, 100% B; 110 – 121 min, 0% B. Eluent was 
collected every minute and combined into 20 fractions. Each fraction was desalted using Supel-
Tips C18 micropipette tips (Sigma – Aldrich). Fractions were solubilized in 50 µL and filtered 




3.2.4 LC – MS Analyses 
Online desalting and reversed-phase chromatography was performed with a Nano liquid 
chromatography (LC) system equipped with an autosampler (Eksigent). Mobile phases A and B 
used for reversed phase (RP)-LC separation of peptides were 3% (v/v) acetonitrile with 0.1% 
formic acid and 100% acetonitrile with 0.1% formic acid, respectively. SCX fractions (10 μL) 
were loaded onto a trapping column (100 µm i.d. x 2 cm), which was packed in house with C18 
200 Å stationary phase material (Michrom Bioresource Inc,) at 3 μL/min in 3% mobile phase B 
for 3 min. After desalting, the sample was loaded onto an analytical column (75 µm i.d. x 13.2 
cm) which was packed in-house with C18 100 Å 3 µm stationary phase material (Michrom 
Bioresource Inc). The gradient was as follows: 0 – 7 min, 10% mobile phase B; 7 – 67 min, 10 – 
30% B; 67 – 75 min, 30 – 60% B; 75 – 77 min, 60 – 90% B; 77 – 82 min, 90% B; 82 – 83 min, 
90 – 10% B; 83 – 95 min, 10% B. The LC eluent was analyzed with positive mode nanoflow 
electrospray using a LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). Data-
dependent acquisition parameters were as follows: the MS survey scan in the Orbitrap (300 – 
1800 m/z) was 120,000 resolution; the top seven most intense peaks were isolated and 
fragmented with collision-induced dissociation (CID) in the LTQ (normalized collision energy of 
35%). Directly after each tandem MS/MS scan, the most intense fragment ion over the m/z range 
200 – 1545 was selected for higher-energy collisional dissociation (HCD) triple staged mass 
spectrometry (MS3). The fragment isolation width was set to 4 m/z, the MS3 AGC was 3 x 105, 
the normalized collision energy was 60%, the resolution was 7,500 and the maximum ion time 





3.2.5 Data Analyses 
RAW files were analyzed with PD 2.1 software (Thermo Scientific) and searched against 
the Uniprot C. elegans database (25,673 sequences). SEQUEST search parameters were as 
follows: two maximum trypsin mis-cleavages, precursor mass tolerance of 10 ppm, fragment 
mass tolerance of 0.8 Da; static modifications were TMT six-plex/+229.163 Da (N-terminus, 
Lys) and carbamidomethyl modification/+57.021 Da (Cys); dynamic modification was oxidation 
modification/+15.995 Da (Met). Decoy database searching was employed to generate medium 
(p<0.05) and high (p<0.01) confidence peptide lists. All the peptides with medium and high 
confidence were used to identify and quantify proteins. To filter peptides, the following 
parameters were applied:  peptide confidence level of medium or high, peptide rank of 1, and 
peptide deviation of 10 ppm. Peptides with a PSM (peptide to spectral match) count of 1 were 
not considered for analysis. The reporter ions (i.e. m/z 126 – 130) were identified with the 
following parameters:  most confident centroid and 20 ppm for reporter ion mass tolerance. 
Furthermore, reporter ion values were normalized 126/130, 127/130, 128/130, and 129/130 and 
final ratio reporting given as 127/126 and 129/128. Proteins belonging to multiple isoforms were 
grouped into a single accession number and final ratios were reported. 
3.3 RESULTS AND DISCUSSION 
In this experiment, C. elegans samples from one biological cohort were analyzed using 




Previously obtained samples (Figure 3.1) were digested using trypsin, labeled using TMT6-plex 
and analyzed using LC – MS/MS and MS3. To obtain MS information, an Orbitrap Elite MS was 















From this analysis, 12215 PSMS, corresponding to 2589 unique peptides (Appendix B 
Table B3.1) and 836 proteins were identified. This number was reduced to 661 proteins when a 
PSM filter of >1 is applied (Appendix B Table B3.2). Between both datasets, 412 proteins and 
1233 peptides were shared across instruments (Figure 3.2); this corresponds to ~40 and 60% of 
proteins and 29% and 47% of peptides in the Orbitrap Velos and Elite, respectively.  
In terms of protein quantification, 416 proteins (i.e. 62%) were quantified in all ratio 
groups (i.e. 126/130, 127/130, 128/130, and 129/130). In comparison, using a stringent filter (≥2 
PSMs per technical replicate) in the Orbitrap Velos data-set (N=897 proteins), 288 proteins 
(~32%) were quantified. A dramatic increase (~100%) of proteins were quantified between the 
two instruments. Since one biological cohort was used in the Elite data-set, proteins were not 
analyzed for statistical – significance; however, general trends about quantified proteins were 
made.  
Among proteins only identified from the Elite (i.e. 249), 134 (i.e. 54%) were also 
quantified across all ratio groups. Using established fold-change values of >1.4 and <0.7 
(Chapter 2), quantified proteins that met this criteria were involved in similar biological 
processes (Appendix B Tables B3.3 – B3.5) as proteins differentially – expressed in Chapter 2. 
Processes related to development, translation, metabolism, reproduction, and cell organization 
were identified in both young- (D1) and aging (D5) adult C. elegans exposed to P. aeruginosa 
PA01 at lower levels (D1 C. elegans) or at higher and lower levels (D5 C. elegans). 
Interestingly, proteins related to translation and cell-redox homeostasis were quantified at lower 
levels in both D1 and D5 C. elegans and at higher levels in D5 C. elegans, respectively. Within 
proteins identified across both data-sets (i.e. 412), 123 (i.e. 30%) were also quantified. Protein 




elegans and 28 proteins differentially – expressed in Chapter 2 (i.e. 51%), were also quantified in 
Elite data-set (Appendix B Table B3.6). This list of proteins included those involved in heat-
shock response, protein folding, and metabolism. 
Overall, results from data acquired on the Elite MS showed a decrease in proteins 
identified but an increase in the number of proteins quantified. Decreases in protein 
identifications are related to analyzing one biological cohort and experimental error. Since one 
biological cohort was analyzed, it was expected that the overlap between proteins identified 
and/or quantified across instruments would be lower. In addition, inefficient sample loading may 
have also contributed to decreased protein identifications. An increase of quantified proteins in 
the Elite, however, is due to improved instrumental parameters. Faster scan rates and higher 
sensitivity on the Elite allows more duty cycles to be performed, thus obtaining more 
quantitative spectra. In addition, the overlap between proteins identified across both instruments 
shows the ability to reproduce similar datasets across different Orbitrap instruments while the 
identification of proteins specific to the Elite displays instrument variability.  
3.4 CONCLUSIONS 
The Elite has many advantages of other Orbitrap hybrid instruments and lower resolution 
systems including its faster scan rate, higher resolution and improved ion optics.  Though usage 
of this instrument did not increase protein identifications, it provided insight about novel and 
similar proteins identified previously in Chapter 2. It also highlighted the potential benefits of 




sampling and experimental error will improve peptide and protein identifications and 





4.0 EVALUATING cPILOT PERFORMANCE OF ORBITRAP INSTRUMENTS TO 
STUDY THE PERIPHERAL PROTEOME OF ALZHEIMER’S DISEASE 
4.1 INTRODUCTION 
Alzheimer’s disease (AD) is both a neurodegenerative and metabolic disease, 
characterized by the main pathogenic hallmarks such as senile plaques and the deposition of 
amyloid beta (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. 
Other features of this disease include metabolic dysfunction,149 insulin resistance,150-151 and 
lower cerebral glucose metabolism.152 While AD affects the brain, it also has implications in 
peripheral organs. For example, cardiovascular disease28, 153-155 is a major risk factor for AD, as 
well as others such as type-2 diabetes, hypertension, obesity and high cholesterol. These 
comorbidities suggest that peripheral organs may contribute to disease pathogenesis, therefore a 
comparative analysis of heart tissues, to others implicated in AD pathogenesis (e.g. brain and 
liver) may give insight into how these tissues contribute to AD pathogenesis. Specifically, 
performing an analysis of brain, heart, and liver tissues from 14-month-old amyloid precursor 
protein/presenilin 1 mice (APP/PS-1) would be beneficial. APP/PS-1, hereafter is referred to as 
(AD) mice, are a double transgenic strain with mutant APPswe and PS1de9 genes.156 This model 
presents many aspects of AD, including the formation and aggregation of amyloid-beta plaques 




pathogenesis of AD 84, 158-160 and our laboratory has initial studies in peripheral tissues such as 
the liver.2 
Multiplexing becomes an effective approach to study the proteome across tissues. This 
technique is used within quantitative proteomics to increase sample throughput by analyzing 
several samples simultaneously in a single MS analysis.  Multiplexing can occur at the protein or 
peptide level and may be executed by metabolic, enzymatic, or chemical reactions. These 
reactions incorporate unique fluorescent tags161-162 or heavy isotopes into proteins or peptides 
from multiple samples, which are pooled and detected by flow cytometry or mass spectrometry.  
The two major groups of techniques used to multiplex in MS are isotopic labeling and isobaric 
tagging. Isotopic labeling allows up to five samples to be analyzed simultaneously in cells71 with 
stable isotopic labeling with amino acids in cell culture (SILAC) or in mammals with stable 
isotopic labeling with amino acids in mammals (SILAM).72 Other techniques incorporate heavy 
isotopes into proteins with isotope protein coded labels (IPCL)163 or 18O exchange,164 or in 
peptides with acetylation165 or dimethylation.71 Isobaric tagging chemically labels proteins or 
peptides with a tag that, upon fragmentation, provides a unique reporter ion at lower m/z values, 
with an intensity corresponding to the protein concentration. Tandem mass tags (TMT),77 
isobaric tag for relative and absolute quantitation (iTRAQ),166 and N,N-Dimethyl Leucine 
(DiLeu)79 tags can analyze as little as two or four samples, or up to as many as 11- 12- and 21-
plex analyses.167-168 Using these multiplexing strategies has provided insight into disease-state 
pathology,84 drug-target studies, and kinetics-based experiments.   
Our laboratory83 and others74, 86, 88, 91 have pushed the limits of multiplexing with 
enhanced multiplexing approaches. Combined precursor isotopic labeling and isobaric tagging 




lysine residues of peptides.83 The flexibility of this method can be adapted to study oxidative 
post-translational modifications such as 3-nitrotyrosine, S-nitrosylation, and cysteine-containing 
peptides.85, 89 In order to maximize the number of quantified peptides and broaden the types of 
analyses that can be studied, different sample preparation strategies and data acquisition methods 
were developed on the LTQ Orbitrap Velos MS instrument. Gas-phase fractionation, two-tiered 
DDA in MS acquisition, and MS3 fragmentation were employed to increase the number of 
dimethylated pairs and reporter ion channels detected and accurately quantified.116  However, 
there are some limitations of conducting a cPILOT analysis on an Orbitrap Velos MS. A major 
challenge is obtaining quantitative information for large numbers of dimethylated pairs and for 
detecting signal for all reporter ion channels used. One strategy to improve this was to use 
selective y1-fragmentation80 of MS/MS fragments for MS3. Another strategy is to increase the 
MS/MS and MS3 signal by using newer Orbitrap Tribrid instruments169-170 (Orbitrap Fusion and 
Orbitrap Fusion Lumos) for MS3 quantification.80 These instruments provide multi-notch MS3 
called synchronous precursor selection (SPS), which allows for multiple MS/MS fragment ions 
to be selected and fragmented, significantly increasing the reporter ion signal.171 Multi-notch 
MS3 increases the number of quantifiable peptides and overall information available about 
relative protein changes across different samples.   
In addition to SPS, the Fusion Lumos has several functions that should improve cPILOT-
analysis including faster scan rates, top speed or top N data dependent acquisition options, and  
targeted mass analysis. The goal here was to evaluate and optimize MS acquisition parameters 
for cPILOT on a Fusion Lumos and compare data for the same samples on the Orbitrap Velos to 
Fusion Lumos instruments. Optimized data analysis parameters for cPILOT-labeled peptides on 




gradient time, m/z isolation window, dynamic exclusion time, targeted analyses nodes, and SPS-
n were tested on fractionated and unfractionated samples. An optimized method was applied an 
AD mouse model to study disease pathogenesis across the brain and periphery (i.e. liver and 
heart). Protein from six biological replicates of tissues of wild-type (WT) and AD mice were 
extracted and peptides were labeled by a cPILOT approach. Since there was a total of 36 samples 
(i.e. six biological replicates, two genotypes and three tissue types), three batches of 12-plex 
cPILOT experiments were performed. Each batch was separated by offline strong cation 
exchange (SCX) and online reversed-phase fractionation prior to MS analysis. Samples were ran 
on the Orbitrap Velos or Fusion Lumos as follows: 1) peptides not subjected to offline 
fractionation and separated with RPLC coupled to the Fusion Lumos, 2) peptides fractionated by 
SCX and separated with RPLC coupled to the Fusion Lumos and 3) peptides fractionated by 
SCX and separated with RPLC coupled to the Orbitrap Velos. Findings from these experiments, 
including the outcome of parameter testing is discussed. These studies provide insight into the 
benefits and challenges of using different Orbitrap instruments for cPILOT analysis. More 
importantly, these studies lay the foundation for using enhanced multiplexing to understand 




4.2 EXPERIMENTAL PROCEDURES 
4.2.1 Animal Husbandry and Ethical Statement 
APP/PS-1 male mice (B6.Cg-Tg(APPswe, PSEN1dE9)85Dbo/Mmjax, stock no. 005864, 
genetic background:C57BL/6J) and heterozygous controls were purchased from Jackson 
Laboratory and housed in the Division of Laboratory Animal Resources at the University of 
Pittsburgh. All animal protocols were approved by the Institutional Animal Care and Use 
Committee at the University of Pittsburgh. Mice were fed standard Purina rodent laboratory 
chow ad libitum and kept in a 12 h light/dark cycle. Brain, heart, and liver tissues were harvested 
from 14-month-old APP/PS-1, referred to as (N = 6) and WT (N = 6) mice and stored at −80 oC.  
4.2.2 Tissue Homogenization, Protein Extraction, and Digestion 
Brain, heart, and liver tissues (i.e. 60 – 80 mg) were homogenized (1× PBS w/ 8M urea) 
with a mechanical homogenizer (MP Biomedicals, LLC) to generate tissue lysates. To extract 
protein, samples were centrifuged (13,000 rpm, 4 oC, 15 min) and supernatant was collected. 
Protein concentration was determined using BCA assay. Protein from brain, heart, and liver 
tissues (~100 µg) was reduced (DTT 1:40 mol ratio), alkylated (IAA 1:80 mol ratio), quenched 
(L-cysteine 1:40 mol ratio), and digested with trypsin (1:50 mol ratio) for 24 h. Peptides were 




4.2.3  cPILOT Labeling 
Peptides (~50 µg) were dissolved in 1% acetic acid (0.25 µg.µL-1). Formaldehyde 
/deuterated formaldehyde (Sigma Aldrich, 8 µL) and sodium cyanoborohydride/-deuteride 
(Sigma Aldrich, 8 µL) are added to either label peptides with light [(-CH3)2] or heavy [(-13CD3)2] 
dimethyl groups, respectively. Peptides were reacted at room temperature for 10 min with 
shaking. To quench the reactions, of 1% ammonia (16 µL) was added for 5 min. Dimethylated 
peptides were re-acidified with 5% formic acid and light and heavy samples, were pooled (Table 
4.1), desalted, and dried down by centrifugal evaporation. Desalted dimethylated peptides were 
dissolved in 100 mM triethyl ammonium bicarbonate (TEAB) buffer and TMT6-plex reagents 
were prepared according to the manufacturer’s protocol. TMT6 -plex reagents were added to 
peptides and reacted at room temperature for 1 h with shaking. cPILOT labeled peptides were 
quenched with 5% (w/v) hydroxylamine-hydrochloride for 15 min and re-acidified with formic 
acid. Peptides were then pooled together into a single sample, concentrated, desalted, and dried 
down an additional time by centrifugal evaporation. Two portions of cPILOT labeled peptides 
were subjected to SCX fractionation while one portion was dissolved in 0.1% formic acid for 




Table 4.1 Experimental Scheme of cPILOT 
TMT6-plex tag 126 (WT) 127 (AD) 128 (WT) 129 (AD) 130 (WT) 131 (AD)
Light DM-Batch 1 Brain  Brain  Heart Heart  Liver  Liver
Heavy DM-Batch 1  Heart Heart  Liver  Liver Brain Brain
Light DM-Batch 2 Liver Liver Heart Heart Brain Brain
Heavy DM-Batch 2 Brain Brain Liver Liver Heart Heart
Light DM-Batch 3 Heart Heart Brain Brain Liver Liver


















4.2.4 Offline SCX Fractionation 
Peptides labeled by cPILOT were fractionated according to the manufacturer’s protocol 
(Protea Biosciences). Briefly, peptides (600 µg) were dissolved in buffer A and loaded onto a 
pre-activated spin column. Peptides were eluted from the spin column in 8 intervals (room 
temperature, 6 min, 4000 × g) with increasing ammonium formate solutions (i.e. 20, 40, 60, 80, 
100, 150, 250, and 500 mM). Fractionated peptides were dried down by centrifugal evaporation 
and dissolved in 0.1% formic acid.   
4.2.5 Liquid Chromatography and Mass Spectrometry Analyses 
Peptides were analyzed using three platforms. 1) Online desalting and reversed-phase 
liquid chromatography (RP-LC) was performed with a nano-UHPLC system equipped with an 
autosampler (Dionex, ThermoFisher Scientific). Mobile phases A and B used for separation were 
(v/v) 0.1% formic acid and 100% ACN with 0.1% formic acid, respectively. Peptides (250 ng) 
were loaded onto a commercial (Thermo Fisher Scientific) trapping column (75 µm x 2 cm) 
containing C18 (3 µm, 100 Å) at 2 µL.min-1 in 0.1% formic acid for 10 min. After desalting, the 
sample was loaded onto an analytical column (100 µm i.d. x 23 cm), which was packed in-house 
with C18 (2.5 µm, 150 Å, Waters).    Four gradients were used as follow:  
a) 0 – 10 min, 10% mobile phase B; 10 – 67 min, 10 – 30% B; 67 – 75 min, 30 – 60% B; 




b) 0 – 10 min, 10% mobile phase B; 10 – 30 min, 10 – 15% B; 30 – 75 min, 15 – 30% B  
75 – 88 min, 30 – 60% B; 88 – 92 min, 60 – 90% B; 92 – 99 min, 90% B; 99 – 100 min, 90 – 
10% B; 100 – 120 min, 10% B. 
c) 0 – 10 min, 10% mobile phase B; 10 – 30 min, 10 – 15% B; 30 – 100 min, 15 – 30% B  
100 – 118 min, 30 – 60% B; 118 – 123 min, 60 – 90% B; 123 – 129 min, 90% B; 129 – 130 min, 
90 – 10% B; 130– 150 min, 10% B. 
Standard data-dependent acquisition parameters were as follows: the MS survey scan in 
the Orbitrap (375 – 1500 m/z) was 120,000 resolution; the most intense peaks with 3s (Top 
Speed) were isolated (0.7 m/z) and fragmented with collision-induced dissociation (CID) in the 
ion trap with an NCE of 35%, AGC of 1 x 104, dynamic exclusion of 20 s, ppm mass tolerance 
of 10, maximum IT of 100 ms. Directly after each MS/MS scan, the four most intense fragment 
ions (over varying m/z ranges) were selected for an additional fragmentation (i.e. MS3) event by 
HCD and analyzed in the OT (scan range: 100 – 400 m/z, isolation width: 2 m/z, AGC: 5 x 104, 
NCE: 55%, resolution: 60,000, maximum IT: 118 ms).  Other parameters such as precursor 
selection range, precursor ion exclusion, and isobaric tag loss exclusion were set as default.  
Targeted inclusion and exclusion tests were performed using the following nodes: 
targeted mass, targeted mass difference, targeted isotopic ratio, and targeted mass trigger. In both 
targeted mass, and targeted mass trigger nodes, a list including m/z, z, m, and retention time 
(targeted mass only) are imported into a list. In targeted mass difference, a mass difference of 
8.0444 Da (Heavy DM – Light DM) and 7.0381 Da (Dimethyl 7-Light DM) were listed, the 
partner intensity range relative to the most intense precursor was set to 70 – 100 %, a subsequent 




similar. For targeted isotopic ratio, similar parameters were added, with the distinction that the 
predicted isotopic range was set to 70 – 100%.  
Parameters including precursor isolation width (experiment 1), dynamic exclusion 
(experiment 3), targeted analyses (experiment 4), and SPS selection (experiment 5) were tested 
and varied as such: Experiment 1, 0.7, 2, or 2.5 m/z; Experiment 3, 0, 10, or 20 s; Experiment 4, 
targeted mass, targeted mass difference, targeted isotopic ratio, and targeted mass trigger; 
Experiment 5,SPS-n of 4, 6, 8 or 10.  
(2) Peptides were loaded onto the same commercial trap column as (1). Separation 
occurred on the same in-house analytical column, but the gradient was adjusted to 1b (see 
above). An optimized MS data acquisition method was applied.  Standard data-dependent 
acquisition parameters were as follows: the MS survey scan in the OT (375 – 1500 m/z) was 
120,000 resolution; the most intense peaks with 3s (Top Speed) were isolated (2m/z) and 
fragmented with CID in the ion trap with an NCE of 35%, AGC of 1 x 104, dynamic exclusion of 
20 s, ppm mass tolerance of 10, maximum IT of 100 ms. Peptide pairs were targeted by using the 
targeted mass difference node. Directly after each MS/MS scan, the ten most intense fragment 
ions (over varying m/z ranges) were selected for an additional fragmentation (i.e. MS3) event by 
HCD and analyzed in the OT (scan range: 100 – 400 m/z, isolation width: 2 m/z, AGC: 5 x 104, 
NCE: 55%, resolution: 60,000, maximum IT: 118 ms).  Other parameters such as precursor 
selection range, precursor ion exclusion, and isobaric tag loss exclusion were set as default.  
(3) Online desalting and RP-LC was performed with a nano-HPLC system equipped with 
an autosampler (Eksigent). Mobile phases A and B used for RP-LC separation of peptides were 
3% (v/v) acetonitrile with 0.1% formic acid and 100% acetonitrile with 0.1% formic acid, 




which was packed in house with C18 (3 µm, 200 Å) stationary phase material (Michrom 
Bioresource Inc,) at 3 μL/min in 3% mobile phase B for 3 min. After desalting, the sample was 
loaded onto an analytical column (75 µm i.d. x 13.2 cm) which was packed in-house with C18 (3 
µm, 100 Å) stationary phase material (Michrom Bioresource Inc). The LC eluent was analyzed 
with positive mode nanoflow electrospray using a LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific). Peptides were loaded onto an in-house trap column (2 cm, 5 µm, 200 
Å) for 3 min (3 µL/min) and separated on an in-house analytical column (75 µm, 13.2 cm) with 
C18 ( 5 µm, 100 Å). The gradient is as follows: 0 – 7 min, 10% mobile phase B; 7 – 27 min, 10 – 
15% B; 27 – 102 min, 15 – 20% B; 102 – 122 min, 20 – 30% B; 122 – 132 min, 30 – 60% B; 
133 – 137 min, 60 – 80% B; 137 – 150 min, 80% B, 150 – 180, 10% B.  Separated peptides were 
detected using a previously described method84 on a LTQ Orbitrap Velos. Briefly, data-
dependent acquisition parameters were as follows: the MS survey scan in the OT (300 – 1800 
m/z) was 60,000 resolution; the top 1 – 7 and top 8 – 14 most intense peaks were isolated and 
fragmented with CID in the LTQ with an NCE of 35%. Directly after each MS/MS scan, the 
most intense fragment ion (over 200 – 1545 m/z) was selected for an additional fragmentation 
(i.e. MS3) by HCD (isolation width: 4 m/z, AGC: 3 x 105, NCE: 60%, resolution: 7500, 
maximum IT: 250 ms). Each fraction was subject to triplicate injections.  
4.2.6 Data Analysis 
Raw files were analyzed with PD v. 2.1 and 2.2 software (Thermo Scientific). Spectra 
were used to obtain sequence information against the Uniprot M. musculus database (01/19/2018, 




miscleavages, precursor mass tolerance of 15 ppm, fragment mass tolerance of 1 Da; static 
modifications were either Dimethyl/+28.031 or 36.028/35.070 Da (N-terminus) and 
carbamidomethyl (Cys) /+57.021 Da; dynamic modifications were TMT six-plex/+229.163 Da 
(Lys) and oxidation (Met) /+15.995 Da. Decoy database searching was employed to generate 
medium (p<0.05) confidence peptide lists. All peptides with medium confidence were used to 
identify and quantify proteins. To filter peptides, the following parameters were applied:  
peptides with a peptide to spectral match (PSM) >1 across biological replicates, peptide 
confidence level of medium, peptide rank of 1, peptide deviation of 10 ppm, and S/N ≥10. The 
reporter ions (i.e. m/z 126 – 131) were identified with the following parameters:  most confident 
centroid and 30 ppm for reporter ion mass tolerance. Furthermore, reporter ion values were 
normalized using internal reference scaling.172  
To identify statistically-significant proteins, a one-way ANOVA was performed in 
Perseus software.173 Proteins with a fold-change of >1.2 or <0.83 were further used for 
bioinformatics analyses in ingenuity pathway analysis (IPA).   
4.3 RESULTS 
Here, we were interested in determining protein changes across WT and AD mice in 
multiple tissues in a single experiment. In addition, because of the advantages of enhanced 
multiplexing offered by cPILOT, insight about changes across biological replicates were also 
identified. The use of TMT reagents in the cPILOT approach requires sample prefractionation 




quantification. As with isobaric tagging strategies, cPILOT also becomes limited in the number 
of proteins that can be quantified compared to the total number of proteins identified. The 
additional steps of sample tagging and clean-up as well as necessary MS3 steps for accurate 
protein quantification116, require longer instrument duty cycles. Thus, less peptides are sampled 
and less proteins are quantified. Previously, cPILOT has been utilized on Orbitrap Velos 
instruments and only recently has the approach been demonstrated on an Orbitrap Fusion Lumos 
instrument.91 Due to the improvements in scan rates, sensitivity, fragmentation and detection 
flexibility, and SPS, the Fusion Lumos dramatically increases the performance of our cPILOT 
strategy. Below, we describe efforts to systematically test the performance of the Fusion Lumos 









Figure 4.1 Experimental Workflow of AD and WT Brain, Heart, and Liver Tissues. Protein (100 µg) was extracted 
from brain, heart, and liver tissues from 14-month old AD and WT mice and digested using trypsin. Peptides 
generated from protein digestion were labeled via cPILOT, pooled, and separated by off-line strong cation exchange 
(SCX) fractionation and reversed-phase HPLC. Fractions were analyzed on either an LTQ Orbitrap Velos or an 
Orbitrap Fusion Lumos. Samples not subjected to fractionation were directly separated by reversed-phase HPLC and 
analyzed on an Orbitrap Fusion Lumos. One sample (not subjected to fractionation) from were used to test the LC 








Specifically, extracted protein from brain, heart, and liver tissues from 14-month old WT 
(N=6) and AD (N=6) mice was digested with trypsin. To accommodate all tissues and biological 
replicates, three pooled sample batches were generated (i.e., Batches 1 – 3). Peptides were 
labeled by using a global cPILOT approach in which peptides are light- or heavy- dimethylated 
at low buffer pH and then tagged with TMT at high buffer pH. After this dual labeling strategy, 
peptides were subjected to different analyses methods. Briefly, a portion of Batch 1 peptides 
were not fractionated and analyzed directly by LC – MS/MS and MS3 on the Fusion Lumos. 
Batch 1-3 peptides were fractionated by SCX and analyzed using either the Fusion Lumos or 
Orbitrap Velos.  
Several experimental parameters were evaluated in each analysis method and included 
those prior to MS introduction and others related to MS acquisition (Figure 4.1). Experiment 1 
tested the effects of increasing the LC gradient from 105 to 150 min and Experiment 2 tested 
different precursor isolation widths from 0.7 to 2.5 m/z.  Experiment 3 tested various dynamic 
exclusion times of 0, 10, and 20 s. Experiment 4 tested different “targeted” acquisition methods 
in the Fusion Lumos, which enable dimethylated pairs to be selectively isolated for MS/MS and 
further MS3 steps.  Lastly, Experiment 5 evaluated SPS in which the number of MS/MS fragment 
ions varied from 4 – 10. 
  An initial demonstration that cPILOT successfully worked in this application of 





Figure 4.2 Comparison of Reporter Ion Spectra from a) and c) Light and b) and d) Heavy Peptides Labeled by 
cPILOT Acquired on a) and b) an Orbitrap Fusion Lumos or c)and d) a LTQ Orbitrap Velos MS Platforms.  
Reporter ions (e.g. 126 – 131) corresponding to peptides N(dimethyl)FVFSLVDAMNGK(TMT6) and 
N(dimethyl)VNVPVIGGHAGK(TMT6) were detected on the Orbitrap Fusion Lumos and LTQ Orbitrap Velos, 
respectively. Light and heavy dimethylated peptides were detected in both phenotypes and all tissue-types and 
correspond to Krebs cycle protein malate dehydrogenase. Notably, reporter ion intensities from the Fusion Lumos is 




 Two peptides that belong to malate dehydrogenase are shown and based on the MS/MS 
data (not shown) these peptides were dimethylated on the N-terminal amines and TMT6-plex 
tagged on the lysine residues. The MS3 spectra for N(dimethyl)VNVPVIGGHAGK(TMT3) for 
light (Figure 4.2a) and heavy (Figure 4.2b) dimethylated pairs have reporter ions detected in 
channels m/z 126-131. For this example peptide, the reporter ion signals show that there is no 
difference in protein level between WT and AD mice for any of the tissues. The enhanced 
multiplexing afforded by cPILOT allows a quick assessment of the consistency of changes in 
WT and AD, as well as in the three tissues from multiple biological replicates. The changes for 
this peptide observed in one biological replicate (Figure 4.2a) are consistent in other replicates 
(Figure 4.2b and data not shown). However, a noticeable difference in signal across tissues is 
apparent, as malate dehydrogenase has higher levels in heart compared to brain and liver, and in 
brain compared to liver tissues. This trend is similar for other peptides detected for this protein as 
shown in Figures 2.4c and 4.2d. It is also apparent that the reporter ion signals are higher from 
the Fusion Lumos data compared to that from the Orbitrap Velos data.  
4.3.1 Evaluation of LC Gradients and Precursor Isolation Windows (Experiments 1 and 2) 
It is expected that increasing the LC gradient would improve the number of proteins 
identified as greater numbers of MS/MS spectra are possible with increased data acquisition 
time. From analysis method 1, samples were injected multiple times to test LC gradient times of 
105, 120, and 150.  Upon increasing the gradient, there was an increase of protein (Figure 4.3a) 
and PSMs (Figure 4.3b) identifications generated from both light and heavy dimethylated 




precursor isolation windows) was 863 proteins from light dimethylated peptides which increased 





Figure 4.3 Comparison of a) Protein and b) Peptide Identification, and c) Quantified Spectra at 105, 120, and 150 
min. Light and heavy dimethylated peptides from a sample not pre-fractionated were identified with increasing LC 
gradient times of 105, 120, and 150 min and widening precursor m/z isolation widths of 0.7, 2.0, and 2.5. a) Protein 
group, b) unique peptide, and PSM IDs increase with gradient time yet decrease with widening the isolation 







This is a 1.3x increase in identifications obtained by increasing the LC gradient by 45 
minutes and is consistent for both light and heavy dimethylated peptides. Higher protein 
identifications is a direct result of higher numbers of PSMs and peptides being obtained (Figure 
4.3b).  PSMs and peptides increased by ~400 – 1800 and ~200 – 1200 respectively, as the 
gradient time increased. The impact of gradient on average numbers of spectra that were 
quantified also increases by 1.5x from 105 min to 150 min. We anticipate that extended gradient 
times would allow more spectra to be quantified and hence proteins identified however, there are 
major considerations with regards to total instrument time. If the experimental design includes 
multiple batches, sample pre-fractionation, and technical replicates then gradient times that are 
shorter will be generally preferred. For the remainder of parameter testing Experiments 2-5, we 
continued with a 150 min gradient time in order to optimize numbers of spectra, peptides, and 
proteins detected.  
For cPILOT analyses it is most critical that both peaks in a light and heavy dimethylated 
pair are isolated at the precursor stage for MS/MS and subsequent MS3. This it to accommodate 
detecting reporter ion signals from all samples present in a batch. The considerations for 
changing the isolation window are that interfering species can be co-isolated from the precursor 
MS spectra if the window is too large whereas lower signal intensities for precursors are carried 
forward into MS/MS if the isolation window is too small. Previously, we evaluated isolation 
window widths for yeasts with DiLeu91 and determined that 0.7 m/z is appropriate. Here, on the 
Fusion Lumos we changed the precursor isolation window from m/z 0.7 to 2.0 and 2.5. The goal 
is to minimize co-isolation of precursors but primarily the co-isolation of light and heavy 
dimethylated peptides while also optimizing the number of pairs selected. Most peptides for this 




in the data acquisition method and those with higher charge states are observed infrequently (9% 
for charge state 4-7) in this experiment. Thus, isolation windows of m/z 2.5 or less are likely 
most appropriate for peptides with a charge state of 2, and will need to be even less to 
accommodate peptides with a charge state of 3. The isolation window in these experiments is 
also impacted by the fact that heavy dimethylated peptides have a peak that shows up 7 Da from 
the light dimethylated peak and is often isolated as the precursor peak in the heavy cluster. 
Increasing isolation windows from m/z 0.7 to 2.0 with a gradient time of 150 min resulted in a 
13-16% decrease of 1212 and 804 proteins to 1054 and 690 proteins from light and heavy 
dimethylated peptides, respectively (Figure 4.3a). Peptides and PSMs followed the same trend 
with increasing isolation windows (Figure 4.3b). On the other hand, the number of quantified 
spectra increased from 57337 to 59517 (Figure 4.3c) which is likely a result of wider windows 
leading to more ion signal at the AGC level; such that the instrument duty cycle is a bit faster in 
this scenario.  However it is apparent that even with greater quantified spectra the number of 
identified peptides and PSMs decreases by 25% from isolation windows of m/z 0.7 to 2.0.  
It is expected that increasing the LC gradient would improve the number of proteins 
identified as greater numbers of MS/MS spectra are possible with increased data acquisition 
time. From analysis method 1, samples were injected multiple times to test LC gradient times of 
105, 120, and 150.  Upon increasing the gradient, there was an increase of protein (Figure 4.3a) 
and PSM (Figure 4.3b) identifications generated from both light and heavy dimethylated 
peptides. For example, the average number of proteins identified at 105 min (across different 
precursor isolation windows) was 863 proteins from light dimethylated peptides which increased 
to 937, and 1106 with gradients of 120 and 150 min respectively (Figure 4.3a). This is a 1.3x 




for both light and heavy dimethylated peptides. Higher protein identifications is a direct result of 
higher numbers of PSMs and peptides being obtained (Figure 4.3b).  PSMs and peptides 
increased by ~400 – 1800 and ~200 – 1200 respectively, as the gradient time increased. The 
impact of gradient on average numbers of spectra that were quantified also increases by 1.5x 
from 105 min to 150 min. We anticipate that extended gradient times would allow more spectra 
to be quantified and hence proteins identified however, there are major considerations with 
regards to total instrument time. If the experimental design includes multiple batches, sample 
pre-fractionation, and technical replicates then gradient times that are shorter will be generally 
preferred. For the remainder of parameter testing Experiments 2-5, we continued with a 150 min 
gradient time in order to optimize numbers of spectra, peptides, and proteins detected.  
For cPILOT analyses it is most critical that both peaks in a light and heavy dimethylated 
pair are isolated at the precursor stage for MS/MS and subsequent MS3. This it to accommodate 
detecting reporter ion signals from all samples present in a batch. The considerations for 
changing the isolation window are that interfering species can be co-isolated from the precursor 
MS spectra if the window is too large whereas lower signal intensities for precursors are carried 
forward into MS/MS if the isolation window is too small. Here, on the Fusion Lumos we 
changed the precursor isolation window from m/z 0.7 to 2.0 and 2.5. The goal is to minimize co-
isolation of precursors but primarily the co-isolation of light and heavy dimethylated peptides 
while also optimizing the number of pairs selected. Most peptides for this dataset haves charge 
state of 2 (48%) and 3 (43%). Peptides with a charge state of 1 are rejected in the data acquisition 
method and those with higher charge states (e.g. 4 – 7) are observed infrequently (9%) in this 
experiment. Thus, isolation windows of m/z 2.5 or less are likely most appropriate for peptides 




state of 3. The isolation window in these experiments is also impacted by the fact that heavy 
dimethylated peptides have a peak that shows up 7 Da from the light dimethylated peak and is 
often isolated as the precursor peak in the heavy cluster. Increasing isolation windows from m/z 
0.7 to 2.0 with a gradient time of 150 min resulted in a 13-16% decrease of 1212 and 804 
proteins to 1054 and 690 proteins from light and heavy dimethylated peptides, respectively 
(Figure 4.3a). PSMs followed the same trend with increasing isolation windows (Figure 4.3b). 
On the other hand, the number of quantified spectra increased from 57337 to 59517 (Figure 4.3c) 
which is likely a result of wider windows leading to more ion signal at the AGC level; such that 
the instrument duty cycle is a bit faster in this scenario.  However it is apparent that even with 
greater quantified spectra the number of identified peptides and PSMs decreases by 25% from 
isolation windows of m/z 0.7 to 2.0.  
4.3.2 Dynamic Exclusion (Experiment 3) 
Next we conducted an experiment that tested the effects of dynamic exclusion on the 
number of peptides and proteins identified (Figure 4.4).  Precursor isolation width was set to m/z 
2.0 and the dynamic exclusion varied from 0 to 10 and 20 s. To assess the quality of the proteins 
that were identified, we evaluated proteins with low, medium, and high confidence as determined 
from PD. Proteins identified considering only light dimethylated peptides came from a larger 
percentage (36 to 69%) of low confidence proteins as the dynamic exclusion went from 20 s to 0 





Figure 4.4 Effects of Dynamic Exclusion Times 0, 10, 20 s on Protein Identifications from a) Light and b) Heavy 
Dimethylated Peptides. Dynamic exclusion times of 0, 10, and 20s was tested to identify if this parameter was 
necessary. An increase of exclusion time resulted in a decrease of protein identifications, yet an increase (~30%) in 
















The same trend was observed for proteins identified from heavy dimethylated peptides 
although the number of total proteins identified was generally lower. Removing dynamic 
exclusion results in over sampling of the same high abundance peptides and more sporadic 
sampling of low abundance peptides, leading to higher numbers of low confidence proteins.  
4.3.3 Targeted Mass Analyses (Experiment 4) 
The above experiments were all conducted with Top Speed (3s) DDA, which is an 
untargeted method. The Fusion Lumos includes targeted inclusion/exclusion nodes are helpful to 
increase the number of dimethylated pairs quantified by removing time spent on R-terminal 
peptides. Among the targeted mass nodes available: targeted mass trigger, targeted mass 
difference, targeted isotopic ratio, and targeted mass (inclusion and exclusion) methods were 
tested (Figure 4.5, Table 4.2).  
Both targeted mass difference and isotopic ratio searched for pairs based on mass 
difference or peptide ratios, whereas the other targeted methods used a list of target m/z, z, M, 
and/or retention times with specified information. Dimethylated PSMs (not shown), had similar 
identifications across the first four methods (i.e. 6599 – 7403 PSMs and 1002 – 1106 proteins) 
whereas a substantial decrease was present in the targeted mass inclusion run (4855 PSMs and 
492 protein groups). Among heavy dimethylated peptides (Figure 4.5d), the targeted mass 
difference method identified 8059 PSMs. The other tests, however, identified ~2-4× (1941 – 






Figure 4.5 Comparison of a) and b) Protein and c) and d) Peptide Identifications of Light and b) Heavy 








Table 4.2 Effects of Targeted Analyses on the Number of PSMs Quantified (Experiment 4). 
Targeted Test
Light Heavy Light Heavy Light Heavy Light Heavy
Targeted Mass Trigger 7378 4265 3159 (42.8) 1725 (40.4) 4079 (55.3) 2440 (57.2) 3985 (97.7) 2375 (97.3)
Targeted Mass Difference 7403 8059 3172 (42.8) 3454 (42.8) 4048 (54.7) 4384 (54.4) 3957 (97.7) 4263 (97.2)
Targeted Isotopic Ratio 7078 3890 3061 (43.2) 1577 (43.2) 3878 (54.8) 2228 (54.8) 3795 (97.9) 2169 (97.4)
Targeted Mass (Exclusion) 6599 3498 2536 (38.4) 1199 (34.3) 3934 (59.6) 2197 (59.6) 3854 (98.0) 2146 (97.7)
Targeted Mass (Inclusion) 1744 1941 47 (2.7) 113 (5.8) 1695 (97.2) 1825 (94.0) 1676 (98.9) 1810 (99.2)
a The number of PSMs and percentage ending with arginine. bThe number of PSMs and percentage ending with lysine. cThe number and 
percentage of lysine ending peptides that are labeled with TMT-6plex.  





In terms of protein quantification, a range of 67-85% of proteins were quantified in at 
least one channel. This percentage decreased to a range of 62-78% when considering proteins 
quantified in all six channels. Over 50% of PSMs identified (Table 4.2) contained lysine and ~ 
97-99% of those peptides were labeled with TMT. Table 4.2 also shows that the targeted mass 
inclusion method was most effective at spending the least amount instrument time on R-
terminated peptides, otherwise increasing the selectivity of the approach.  
Experiment 4 provided insight into which targeted analyses would be helpful in selecting 
dimethylated peptide pairs during MS acquisition. It was confirmed that targeted mass and 
targeted mass trigger tests inefficiently increased the quantity of peptide pairs since a) targeted 
mass inclusion only selected K-terminating peptides on the inclusion list, b) targeted mass 
exclusion did not remove all R-terminated peptides, and c) targeted mass trigger worked 
similarly to a and b. Though b) only selected K-terminated peptides, it would not be ideal for 
global analyses as only selected a fraction of the peptide m/z values on the list.  Conversely, 
targeted mass difference and targeted mass isotopic ratio tests were expected to identify and 
quantify similar amounts of proteins, and thus an increase of dimethylated pairs. However, 
targeted mass difference identified more light and heavy PSMs combined (15,462) than targeted 
isotopic ratio (10,966) and greater percentages (70 and 81% vs. 59 and 77%) of light and heavy 
dimethylated pairs, respectively. Based on these data, the best method for conducting targeted 





4.3.4 Synchronous Precursor Selection (Experiment 5) 
Multi-notch MS3 uses between 2 – 20 fragment ions for quantification, thus increasing 
the signal present in reporter ion channels in comparison to single-notch MS3. In experiment 5, a 
range of 4-10 SPS ions were tested, resulting in similar amounts of proteins being identified and 
quantified in at least one channel (Table 4.3).  
Proteins were considered quantified if the S/N ≥10 for a given reporter ion channel and 
the minimal signal above the set threshold. Among proteins quantified in six channels, the largest 
increase (65 – 72%) was present with SPS-10. In terms of peptide quantification (not shown), 
similar percentages of peptides containing lysine at the C-terminus (~55%) of which ~97-98% 
were labeled with TMT. While SPS-4 generated the largest number of MS/MS (116,113) and 
more importantly, quantified spectra (59713) compared to SPS-10, SPS-10 had the greatest 





Table 4.3 Effects of SPS Parameters on the Number of Protein IDs (Experiment 5). 
SPS-Nb MS/MS Spectra Quan. Spectra
Light Heavy Light Heavy Light Heavy Light/Heavy Light/Heavy
4 1051 748 725 (69) 540 (72) 682 (65) 501 (67) 116113 59713
6 1042 722 729 (70) 517 (72) 707 (68) 492 (68) 116017 59528
8 1077 735 760 (71) 532 (72) 733 (68) 513 (70) 113097 57995
10 1056 702 770 (73) 514 (73) 756 (72) 509 (73) 113266 58131
Protein Groups Proteinsc: 1 Channel (%) Proteinsd: 6 Channels (%)
a Isolation window 2 m/z. b The number of fragment ions used to for synchrous precursor selection (SPS). c The number and 
percentage of proteins quantified in at least one reporter ion channel.  cThe number and percentage of proteins quantified in all 

















4.3.5 Comparisons of Samples Analyzed by Velos and Fusion Lumos Instrumentation 
Unfractionated and fractionated samples were compared to identify how differences in 
Orbitrap instrumentation may affect protein identification and quantification. Across three 
cPILOT 12-plex batches and three different sample analyses methods, over >600,000 PSMs 
(Table 4.4) corresponding to >22,000 unique peptides and 6074 protein groups (Figure 4.6) were 
identified (Appendix C Tables C4.1 – C4.8).  
Sample fractionation dramatically increased the number of peptides and proteins 
identified on the Orbitrap Velos (Appendix C Tables C4.1 and C4.2) and Fusion Lumos 
(Appendix C Tables C4.3 and C4.4), compared to un-fractionated samples on the Fusion Lumos 
(Figures 4.6a and 4.6b, Appendix C Tables C4.5 and C4.6). Similarities in protein identifications 
(Figure 4.6a) range from 19 – 65% with the least overlap occurring between unfractionated and 
fractionated datasets from different instruments. However, each approach still observed unique 
proteins. Peptides shared similar behavior across approaches (Figure 4.6b). Overall, 910 proteins 
were identified in all approaches. Among all 6074 identified proteins, 70% were identified with 
>2 PSMs (Figure 4.7). Interestingly, a criterion of excluding single PSMs was reconsidered 
based on the data shown. An observation of six reporter ions shows that the peptide was still 
present in six different samples. Some vital information may be diagnosed with this criterion. As 
the number of PSMs increase from 11 – 100, 101 – 1001, and so forth, the number of proteins 
identified decreases.  Among proteins identified by 1 PSM (Figure 4.7c insert), most were 




Table 4.4 Effects of SCX Fractionation on the Number of Proteins and PSMs Identified. 
SPS-Na Protein Groupsb Proteinsc (%) PSMS ID Rd Ke TMT-Kf
Batch 1-3, 8 Fractions, Velos 1 2199 142 (14) 374951 133759 (35.7) 236177 (63.0) 234114 (99.1)
Batch 1-3, 0 Fractions, Lumos 10 1848 334 (26) 44620 17851 (40.0) 25959 (58.2) 25498 (98.2)
Batch 1-3, 8 Fractions, Lumos 10 4968 1012 (28) 223286 87840 (39.3) 129797 (58.0) 127791 (98.0)
a The number of fragment ions used to for synchrous precursor selection (SPS). b The number of proteins identified with more than 1 PSM. cThe 
number and percentage of proteins quantified in all reporter (i.e. 126 - 131) ion channels across all experimental groups.  dThe number and 
percentage of peptides ending with arginine a.  eThe number and percentage of peptides ending with lysine. fThe number and percentage of 





Figure 4.6 Identification of a) Protein and b) Peptide Groups Identified Across Three MS Experiments. a) Proteins 
identified from 8-fractions on the Orbitrap Velos (N=2199) were compared to proteins identified from 8-fractions on 
the Fusion Lumos (N=4968) and non-fractionated on the Fusion Lumos (N=1848). Across all three experiments, 
6074 proteins were identified, with 910 proteins (~15%) being present in all groups. This total number corresponds 






Figure 4.7 Distribution of PSMs within Identified Proteins. Proteins were identified from a range of 1 - >10000 
PSMs per protein. Zoomed-in views of proteins identified from 1 PSM (top right) or 11 – 100 PSMs (bottom right), 
shows that most proteins identified by one 1 PSM were quantified in either 0 or 6 channels and that most proteins 




 Generally, K-terminated peptides were selected ~58 – 63% (Table 4.4) for MS analysis 
across analysis methods and these peptides had a TMT6 –plex labeling efficiency of 98% (Table 
4.4). To compare reporter ion intensities across MS platforms, protein intensities shared across 
fractionated datasets (Figure 4.8) were compared. Proteins quantified in both fractionated 
datasets (N=846), had higher intensities of ~1 order of magnitude from the Fusion Lumos. This 





Figure 4.8 Correlation of Reporter-Ion Intensities from Proteins Present in Both Fractionated Datasets. After 
performing data normalization and statistics, reporter ion intensities corresponding proteins quantified were 
compared across fractionated datasets (N=846). Protein intensities increased by ~10× (see zoomed-in region) upon 
quantification by the Fusion Lumos. The reduction of the number of proteins quantified in both datasets is due to the 











4.3.6 Differentially – Expressed Proteins in AD Brain, Heart, and Liver Tissues 
System-wide changes in AD were evaluated in brain, heart, and liver proteins from WT 
and AD mice (Figure 4.9). Data used for statistical analysis was acquired from the Fusion 
Lumos. Eighty-five (N=39 brain, N=14 heart, and N=32 liver) varied significantly between AD 
and WT samples (p<0.05) with eight proteins varying substantially (p<0.001) in the brain or 
liver (Figures 4.9a and 4.9c). The most notable changes occurred in Apolipoprotein E in the 
brain (p=6.14E-6) and proteolytic protein MCG15081 (p=9.67E-5) in the liver.  
Proteins that had both a p<0.05 and a fold-change of >1.2 or <0.83 (N=23, Table 4.5- 
bolded) were further analyzed with Ingenuity Pathway Analysis (IPA). Canonical pathways 
related to cell signaling were significant among brain proteins (Figure 4.10a), where pathways 
related to biosynthesis, degradation, and fatty acid oxidation were identified among liver proteins 
(Figure 4.10b). As expected, the molecular function lipid metabolism was also identified in both 








Figure 4.9 Volcano plots of Brain, Heart, and Liver Proteins as a Function of Disease. Normalized and filtered 
proteins were compared using a one-way-ANOVA. Proteins with a p <0.05 are present above the horizontal line 




Table 4.5 Differentially – Expressed Proteins in the Brain, Heart, and/or Liver.  
Accession Protein Description (short) AD/WT Brain p-value brain AD/WT Heart p-value heart AD/WT Liver p-value liver
Q792Y8 MCG15081 1.08 ± 0.13 7.70E-02 1.07 ± 0.16 2.90E-01 1.20 ± 0.089 9.67E-05
A0A075B5P6 Ig mu chain C region (Fragment) 1.00 ± 0.27 9.90E-01 0.89 ± 0.26 2.40E-01 0.82 ± 0.35 9.99E-02
A2AEG6 Glycoprotein m6b, isoform CRA_g 0.80 ± 0.33 9.73E-02 0.92 ± 0.24 - 0.96 ± 0.24 -
A2AWI7 Endophilin-B2 0.99 ± 0.25 7.50E-01 0.94 ± 0.36 - 1.21 ± 0.27 2.94E-01
B0QZN5 Vesicle-associated membrane protein 2 0.80 ± 0.34 8.75E-02 0.90 ± 0.19 - 0.97 ± 0.22 -
B1ATI0 Aldehyde dehydrogenase 1.07 ± 0.11 4.60E-01 1.02 ± 0.27 - 1.22 ± 0.24 1.89E-02
B9EKP8 Sorbin and SH3 domain-containing protein 2 0.83 ± 0.24 1.24E-01 0.97 ± 0.21 6.50E-01 1.13 ± 0.12 -
E9Q0H6 Fatty acid-binding protein, brain 1.46 ± 0.61 5.44E-03 1.02 ± 0.26 8.70E-01 0.98 ± 0.049 8.40E-01
E9Q827 cAMP-regulated phosphoprotein 19 0.82 ± 0.44 2.24E-01 1.03 ± 0.12 8.00E-01 1.08 ± 0.055 6.00E-01
E9QN63
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 1 0.83 ± 0.25 1.02E-01 0.86 ± 0.21 - 1.09 ± 0.093 -
O08532
Voltage-dependent calcium channel subunit alpha-
2/delta-1 0.81 ± 0.29 1.81E-01 1.04 ± 0.43 8.30E-01 0.98 ± 0.19 -
O08715 A-kinase anchor protein 1, mitochondrial 1.24 ± 0.32 1.36E-01 0.88 ± 0.14 8.90E-02 1.22 ± 0.084 3.59E-04
O35381
Acidic leucine-rich nuclear phosphoprotein 32 family 
member A 1.07 ± 0.29 4.50E-01 1.22 ± 0.29 5.66E-02 1.04 ± 0.076 2.60E-01
O88935 Synapsin-1 0.81 ± 0.31 9.65E-02 0.99 ± 0.19 - 1.01 ± 0.087 9.40E-01
P01831 Thy-1 membrane glycoprotein 0.68 ± 0.39 4.59E-02 0.96 ± 0.069 - 1.02 ± 0.083 -
P06330 Ig heavy chain V region AC38 205.12 1.24 ± 0.57 - 0.63 ± 0.18 1.66E-02 0.70 ± 0.20 4.46E-02
P06801 NADP-dependent malic enzyme 1.10 ± 0.21 4.10E-01 1.07 ± 0.18 3.90E-01 1.42 ± 0.31 1.28E-03
P08226 Apolipoprotein E 2.10 ± 0.38 6.14E-06 1.02 ± 0.12 9.10E-01 1.13 ± 0.079 6.80E-02
P11404 Fatty acid-binding protein, heart 1.02 ± 0.22 - 1.23 ± 0.46 8.01E-02 0.97 ± 0.28 -
P14211 Calreticulin 1.11 ± 0.027 2.14E-02 1.06 ± 0.11 4.70E-01 0.96 ± 0.046 1.90E-01
P16015 Carbonic anhydrase 3 1.07 ± 0.20 - 1.01 ± 0.17 9.40E-01 1.28 ± 0.27 7.80E-04
P18242 Cathepsin D 1.24 ± 0.093 9.72E-04 1.01 ± 0.086 7.90E-01 0.99 ± 0.097 9.10E-01
P26041 Moesin 1.26 ± 0.29 6.22E-02 1.02 ± 0.075 8.80E-01 1.00 ± 0.093 9.70E-01
P34022 Ran-specific GTPase-activating protein 1.07 ± 0.21 4.80E-01 1.21± 0.25 2.27E-01 1.00 ± 0.17 -
P35802 Neuronal membrane glycoprotein M6-a 0.73 ± 0.32 7.02E-02 1.13 ± 0.18 - 1.00 ± 0.12 -
P35980 60S ribosomal protein L18 0.75 ± 0.19 4.82E-02 1.04 ± 0.20 8.60E-01 0.82 ± 0.24 1.20E-01
P43006 Excitatory amino acid transporter 2 0.82 ± 0.56 2.98E-01 0.99 ± 0.16 - 1.04 ± 0.18 -
P46978
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A 1.15 ± 0.19 2.80E-01 1.25 ± 0.41 1.38E-01 1.00 ± 0.18 9.30E-01
P48036 Annexin A5 1.29 ± 0.60 1.67E-01 1.03 ± 0.086 7.30E-01 1.09 ± 0.12 1.70E-01
P52196 Thiosulfate sulfurtransferase 1.22 ± 0.60 1.57E-01 1.07 ± 0.12 6.50E-01 1.03 ± 0.18 5.10E-01
P54822 Adenylosuccinate lyase 1.20 ± 0.60 1.45E-01 1.02 ± 0.22 8.80E-01 1.00 ± 0.098 9.90E-01
P56382 ATP synthase subunit epsilon, mitochondrial 1.24 ± 0.28 1.74E-01 0.91 ± 0.26 - 1.04 ± 0.21 -
P57759 Endoplasmic reticulum resident protein 29 1.32 ± 0.47 2.32E-02 1.08 ± 0.054 4.50E-01 0.98 ± 0.11 7.20E-01
P61027 Ras-related protein Rab-10 0.95 ± 0.28 6.00E-01 1.10 ± 0.27 - 1.26 ± 0.37 7.36E-02
P62281 40S ribosomal protein S11 0.80 ± 0.26 9.67E-02 0.95 ± 0.28 - 1.07 ± 0.25 5.10E-01
P63037 DnaJ homolog subfamily A member 1 0.98 ± 0.22 8.30E-01 1.21 ± 0.20 1.89E-01 1.04 ± 0.13 6.50E-01
P84091 AP-2 complex subunit mu 0.82 ± 0.31 8.00E-02 1.03 ± 0.18 - 0.99 ± 0.051 8.40E-01
Q06890 Clusterin 1.61 ± 0.81 1.79E-02 0.92 ± 0.20 3.60E-01 0.93 ± 0.075 4.40E-01
Q62277 Synaptophysin 0.80 ± 0.34 1.10E-01 1.05 ± 0.15 - 1.04 ± 0.10 -
Q64176 Carboxylesterase 1E 1.24 ± 0.094 - 0.90 ± 0.24 - 1.22 ± 0.10 1.50E-01
Q6AXD2 Abi2 protein 0.71 ± 0.33 5.67E-02 0.96 ± 0.55 - 1.09 ± 0.20 -
Q6P6I8 Signal-regulatory protein alpha 0.76 ± 0.35 1.57E-01 1.34 ± 0.69 - 1.04 ± 0.093 -
Q71KT5 Delta(14)-sterol reductase 0.99 ± 0.22 - 1.09 ± 0.22 - 1.20 ± 0.27 3.65E-02
Q8BG32 26S proteasome non-ATPase regulatory subunit 11 0.97 ± 0.19 7.10E-01 1.25 ± 0.40 4.88E-02 0.97± 0.074 4.40E-01
Q8CAA7 Glucose 1,6-bisphosphate synthase 0.83 ± 0.32 1.31E-01 1.17 ± 0.28 - 0.95 ± 0.14 -
Q8CBB6 Histone H2B OS 1.18 ± 0.89 - 1.21 ± 0.46 2.08E-01 1.03 ± 0.16 8.40E-01
Q8VCH0 3-ketoacyl-CoA thiolase B, peroxisomal 1.05 ± 0.18 - 0.99 ± 0.13 9.40E-01 1.35 ± 0.26 2.80E-04
Q8VIJ6 Splicing factor, proline- and glutamine-rich 1.12 ± 0.30 2.90E-01 1.25 ± 0.20 1.87E-01 1.01 ± 0.094 9.00E-01
Q91X83 S-adenosylmethionine synthase isoform type-1 0.92 ± 0.25 - 1.20 ± 0.27 - 1.23 ± 0.35 1.25E-02
Q920E5 Farnesyl pyrophosphate synthase 1.20 ± 0.23 2.10E-01 0.99 ± 0.22 - 1.28 ± 0.53 3.66E-02
Q923D2 Flavin reductase (NADPH) 1.21 ± 0.34 1.49E-01 1.05 ± 0.18 6.70E-01 1.05 ± 0.077 1.60E-01
Q99J39 Malonyl-CoA decarboxylase, mitochondrial 1.05 ± 0.16 6.80E-01 1.27 ± 0.45 5.72E-02 0.99 ± 0.23 8.90E-01
Q99LB6 Methionine adenosyltransferase 2 subunit beta 1.06 ± 0.19 4.30E-01 1.22 ± 0.20 1.89E-01 1.09 ± 0.22 3.60E-01
Q99N87 28S ribosomal protein S5, mitochondrial 0.80 ± 0.16 7.32E-02 1.21 ± 0.24 2.31E-02 1.08 ± 0.12 2.60E-01
Q99PL6 UBX domain-containing protein 6 0.96 ± 0.14 6.40E-01 1.02 ± 0.12 9.10E-01 1.20 ± 0.19 2.18E-01
Q9CQI6 Coactosin-like protein 1.28 ± 0.37 1.95E-02 0.90 ± 0.13 - 1.08 ± 0.17 4.30E-01
Q9CRD0 OCIA domain-containing protein 1 0.73 ± 0.23 2.62E-02 0.98 ± 0.40 - 0.73 ± 0.20 9.70E-02
Q9CXS4 Centromere protein V 1.07 ± 0.11 3.70E-01 1.23 ± 0.34 1.69E-01 0.98 ± 0.17 7.70E-01
Q9CYT6 Adenylyl cyclase-associated protein 2 0.83 ± 0.38 1.90E-01 1.03 ± 0.12 7.50E-01 1.00 ± 0.10 -
Q9CZ44 NSFL1 cofactor p47 1.13 ± 0.34 1.60E-01 1.20 ± 0.28 2.49E-01 1.20 ± 0.18 1.09E-01
Q9D0F9 Phosphoglucomutase-1 1.25 ± 0.40 7.34E-02 1.00 ± 0.055 9.90E-01 1.08 ± 0.067 1.40E-01
Q9DAW9 Calponin-3 1.26 ± 0.43 4.43E-02 1.20 ± 0.27 - 1.06 ± 0.39 5.90E-01
Q9QYB8 Beta-adducin 0.81 ± 0.37 1.88E-01 1.27 ± 0.27 - 0.96 ± 0.12 8.10E-01
Q9Z1Q5 Chloride intracellular channel protein 1 1.29 ± 0.34 2.10E-02 1.05 ± 0.069 5.50E-01 1.02 ± 0.087 8.20E-01
Q9Z2Q6 Septin-5 0.81 ± 0.37 1.29E-01 1.00 ± 0.25 9.90E-01 1.00 ± 0.098 -
V9GX76 Unconventional myosin-VI 1.20 ± 0.26 6.12E-02 0.93 ± 0.16 - 1.04 ± 0.19 7.70E-01





Figure 4.10 Canonical Pathways of Statistically-Significant Proteins in a) Brain and b) Liver Tissues.  Pathways 







The most biological information is gained from cPILOT experiments when quantitative 
information is obtained from all samples. To achieve this goal, high labeling efficiencies are 
necessary, both light and heavy dimethylated pairs must both be selected for tandem MS 
analysis, and selected peptides must generate reporter ion intensities above the minimum 
threshold. On the Orbitrap Velos platform, quantitative information was gained from all samples 
by 1) implementing offline SCX fractionation, 2) applying a two-tiered DDA method to select 
both high- and low abundant peptides and 3) using longer LC gradients and MS3 quantification. 
The tradeoffs of this two-tiered DDA approach are, increased sample and data analysis times and 
due to single-notch MS3, missing reporter ion channels. The Fusion Lumos dramatically 
improved the performance of the cPILOT analysis and increased the number quantified 
dimethylated peptide pairs.  
4.4.1 cPILOT Method Optimization Experiments (Fusion Lumos) 
To modify cPILOT analysis for the Fusion Lumos, the LC gradient time, precursor 
isolation window, dynamic exclusion time, targeted analyses, and SPS-N were varied. These 
experiments identified and quantified similar amounts of proteins without SCX fractionation, in 
comparison to the Orbitrap Velos. This was due to a number of factors, including the improved 
analytical separation of peptides, increased scanning speed of both the Orbitrap and ion trap 
mass analyzers and the improved resolution of identified peptides. Fractionated peptides were 




comparison. Between these two datasets, the Fusion Lumos generated more proteins and 
peptides identifications.  Overall, targeted mass difference and SPS-N parameters were most 
critical for improving the effectiveness of cPILOT analysis on the Fusion Lumos. The targeted 
mass difference function specifies the number of precursors within a group by the difference in 
mass, thus selecting one peak within the peptide pair or both peptides in the pair. This function 
increased the number of light and heavy dimethylated pairs overlap to ~70 – 80% across all 
sample channels, thus increasing the percentage of proteins which have quantitative information. 
In addition, the use of SPS-MS3 improved the percentage of proteins quantified in all channels 
by ~20%, in comparison to the Orbitrap Velos thus improving the ability to quantify less 
abundant proteins.  
Challenges related to analyzing cPILOT on the Fusion Lumos were related to the 
selection of peptide pairs and quantifying low abundant peptides. Light dimethylated peptides 
were selected for isolation and fragmentation more frequently than heavy dimethylated peptides. 
This is problematic as not fragmenting both peaks in a pair reduces the amount of information 
that can be learned. In addition, lower abundance proteins have more missing reporter ion 
channels or low S/N reporter ions. Overall, it was extremely worthwhile to evaluate different 
instrumental parameter methods for cPILOT. This gave the foundation of the AD study herein 
where proteome changes across tissues types and disease were investigated. 
4.4.2 AD Pathogenesis from Brain, Heart, and Liver Tissues 
cPILOT was applied to AD brain, heart, and liver tissues to understand the contribution 




clathrin-mediated endocytosis signaling (Figure 4.10a) and cholesterol biosynthesis (Figure 
4.10b) are known to occur in AD.174-176 Differentially – expressed proteins apolipoprotein E and 
clusterin, proteins well-known in AD brain pathogenesis,177-178 were higher in expression in the 
brain in this study. In the liver, mostly metabolic proteins, including aldehyde dehydrogenase, 3-
ketoacyl-CoA thiolase-B, peroxisomal, and NADP-dependent malic enzyme were higher in AD 
mice compared to WT. These proteins are involved in glycolysis/gluconeogenesis and the Krebs 
cycle and may contribute to dysregulated metabolism identified in AD.179-180 In the heart, 28s 
ribosomal protein S5, mitochondrial, and 26S proteasome non-ATPase regulatory subunit 11 are 
related to protein synthesis and folding were higher in AD mice. Immunoglobulin protein, Ig 
heavy chain V region AC38 205.12, was lower in AD mice in both heart and liver tissues, and 
may be involved in eliciting an immune response.181 Proteins related to electron transport and 
metabolism were at higher levels in the heart which has been related to mitochondrial 
dysfunction.182 In addition, proteins related to metabolism, protein folding, peptide synthesis, and 
oxidative stress were higher in the in the brain and liver of AD mice compared to WT. 
Across tissues, quantified proteins (Figure 4.11) in both WT and AD were mostly present 
in all tissues.  MA plots of quantified tissues show that proteins across tissues have a wide range 
of changes (Figure 4.12) with ratios >4-fold. Interestingly, brain vs. liver proteins (in both WT 
















These experiments have provided insight into 1) cPILOT performance on two Orbitrap 
instruments and 2) understanding the peripheral proteome of AD. Successful cPILOT analysis on 
the Fusion Lumos was achieved by using longer LC gradients, targeted mass difference, a wider 
precursor isolation window, and increase of SPS ions to identify more dimethylated peptide pairs 
and to increase the percentage of quantified data. With both the Orbitrap Velos and Fusion 
Lumos capable of cPILOT analysis, this multiplexing strategy is versatile and can be applied to a 
host of Orbitrap MS platforms and experimental studies. As a function of disease, an increase of 
metabolic processes, including carbohydrate, lipid, and peptide metabolism occurs across tissues, 
with the most prominent changes occurring in the brain and liver. Though there was minimal 
overlap in the number of statistically – significant proteins across tissues, the similarity of 
molecular functions may indicate that AD pathogenesis occurs similarly across these tissues, but 





5.0 PROTEOMICS ANALYSIS OF HUMAN POSTMORTEM TISSUES IN 
ALZHEIMER’S DISEASE 
5.1 INTRODUCTION 
 Alzheimer’s disease (AD) is a neurodegenerative disorder that results in cognitive 
decline. Classical hallmarks of this disease include the deposit of amyloid beta (Aβ) plaques and 
neurofibrillary tangles. It is also a metabolic disorder that causes lower cerebral glucose 
metabolism,183-185 dysregulated lipid metabolism,149, 186-187 and increased insulin resistance.188-190  
These changes are well-defined in the brain, but are also present in the periphery. Altered 
metabolic processes in skin fibroblasts191 and mitochondrial dysfunction in lymphocytes192 
suggests that the periphery may be involved in AD pathogenesis.  One peripheral tissue that has 
been implicated in AD is the liver. This tissue is responsible for protein synthesis, detoxification, 
and metabolizing molecules. It is also responsible for degrading and clearing Aβ peptides.193-195 
The proteomics analysis of liver tissues from amyloid precursor protein/presenilin-1 (APP/PS-1) 
mice in our laboratory,84 identified changes related to carbohydrate and fatty – acid metabolism, 
transcription and translation, and redox signaling. These pathways highlight that AD is a 
metabolic disorder.  Another tissue that may be involved in AD pathogenesis is the heart. This 
organ is a part of the circulatory system and pumps blood, which provides oxygen and nutrients 




hypertension, diabetes, obesity, and smoking are also risk-factors in AD.154 Pre-clinical markers 
of CVD (e.g. intima media thickness,196 carotid plaques,196-197 lacunae,198-199 and white matter 
lesions200-201)  are also more prevalent in AD. One hypothesis is that CVD risk factors cause 
brain hypoperfusion, which results in cognitive decline and increases the chances of developing 
AD.202 Generally though, the molecular mechanisms of how the heart may contribute to AD 
pathogenesis are still poorly understood.28, 203-205   
Proteomics analyses of peripheral cells and tissues have been performed on ante-/post-
mortem samples from humans and model organisms. Plasma,206 cerebrospinal fluid,207 and blood 
derived lymphocytes192 have been studied, identifying inflammatory and metabolic proteins 
related to AD progression.  Post-mortem proteomics analyses of tissues have been performed 
using brain regions (e.g. hippocampus,208 cortical samples,209 olfactory bulb,210 prefrontal 
cortex,211 and temporal neocortex212), and result in changes related to immune response, 
metabolism, and apoptosis.  Proteomics analyses of peripheral tissues in AD have been limited to 
mouse models. In these studies, splenocytes213 and liver84 samples were studied in 14-month-old 
APP/PS-1 mice, resulting in changes in glucose metabolism, electron transport, and oxidative 
phosphorylation. Most recently, a multi-tissue analysis was performed, comparing brain, heart, 
and liver tissues from this model (Chapter 4). APP/PS-1 is a human double transgenic mouse 
model which develops amyloid-beta plaques and has cognitive decline with increasing age.156 
Here, we designed a translational study to obtain a more direct understanding of how the 
periphery may be involved in AD pathogenesis. Brain (superior frontal gyrus), heart, and liver 
tissues from AD (Braak stages IV and V) and cognitively normal (CN) controls were analyzed 
using quantitative proteomics techniques. The SFG is a part of the frontal lobe and is responsible 




Combined precursor isotopic labeling and isobaric tagging (cPILOT), an enhanced 
multiplexing strategy has been implemented.80, 83, 91 This method allows up to 24 samples to be 
analyzed simultaneously91, thus increasing sample throughput while decreasing instrumental 
analysis time. Similarities and differences across both disease-state and tissue-type have been 
directly compared within one experiment. Results from these experiments provide insight into 
understanding how the periphery contributes to late – onset AD, thus revealing similarities and 
differences across these tissues response to disease. 
5.2 EXPERIMENTAL PROCEDURES 
5.2.1 Tissue Harvesting and Ethical Statement 
Frozen human brain (superior frontal gyrus), heart, and liver tissues were collected post-
mortem from 3 AD patients and 3 cognitively normal control subjects (Table 1). The AD cases 
were neuropathologically diagnosed as CERAD-NP definite AD, Braak stages IV and V. All 
samples were obtained from Banner Sun Health Research Institute (Sun city, AZ). Samples were 
collected 3-5 hours post-mortem, frozen, and stored at -80 oC prior to sample handling. The 
collection of brain, heart, and liver tissues and the conducted research had been approved by the 







Table 5.1 AD and CN Subject Clinical and Neuropathological Data. 
patient case gender race age Braak stage
1 control male Caucasian 79 II
2 control male Caucasian 74 I
3 control male Caucasian 87 III
4 AD male Caucasian 77 IV
5 AD male Caucasian 87 V


















5.2.2 Tissue Homogenization, Protein Extraction, and Digestion 
Brain, heart, and liver tissues were homogenized with a mechanical homogenizer 
(Fastprep 24) to generate tissue lysates. To extract protein, samples were centrifuged (13,000 
rpm, 4 oC, 15 min) and supernatant were collected. Protein concentration was determined using 
BCA assay. Protein from brain, heart, and liver tissues (~100 µg) was reduced (DTT 1:40 mol 
ratio), alkylated (IAA 1:80 mol ratio), quenched (L-cysteine 1:40 mol ratio), and digested with 
trypsin/lys-c (1:100 mol ratio) for 8 h. Peptides were desalted using a HLB cartridge and dried 
down using centrifugal evaporation. Prior to labeling by cPILOT, peptide concentration was 
determined by using BCA assay.  
5.2.3 cPILOT Labeling 
Peptides (~50 µg) were dissolved in 1% acetic acid (0.25 µg.µL-1). Formaldehyde 
/deuterated formaldehyde (Sigma Aldrich, 8 µL) and sodium cyanoborohydride/-deuteride 
(Sigma Aldrich, 8 µL) are added to either label peptides with light [(-CH3)2] or heavy [(-13CD3)2] 
dimethyl groups, respectively. Peptides were reacted at room temperature for 10 min with 
shaking. To quench the reactions, of 1% ammonia (16 µL) was added for 5 min. Dimethylated 
peptides were re-acidified with 5% formic acid and light and heavy samples, were pooled (Table 
5.2), desalted, and dried down by centrifugal evaporation. Desalted dimethylated peptides were 
dissolved in 100 mM triethyl ammonium bicarbonate (TEAB) buffer and TMT6-plex reagents 
were prepared according to the manufacturer’s protocol. TMT11-plex reagents were added to 




cPILOT were quenched with 5% (w/v) hydroxylamine-hydrochloride for 15 min and re-acidified 
with formic acid. Peptides were then pooled together into a single sample, concentrated, 
desalted, and dried down an additional time by centrifugal evaporation.  
Table 5.2 Experimental Scheme of cPILOT 
TMT11-plex tag 126 127n 127c 128n 128c 129n 129c 130n 130c 131n 131c
Light DM  Pool 1 CN Liver 1 AD Liver 1 CN Liver 2 AD Heart 2 CN Heart 3 AD Heart 3 CN Brain 1 AD Brain 1 CN Brain 2 Pool 2




5.2.4 Offline SCX Fractionation 
Peptides were fractionated according to the manufacturer’s protocol (Protea Biosciences). 
Briefly, peptides (600 µg) were dissolved in buffer A and loaded onto a pre-activated spin 
column. Peptides were eluted off the spin column in 8 intervals (room temperature, 6 min, 4000 
× g) with increasing ammonium formate solutions (i.e. 20 mM, 40 mM, 60 mM, 80 mM, 100 
mM, 150 mM, 250 mM, and 500 mM). Fractionated peptides were dried down by centrifugal 
evaporation and dissolved in 0.1% formic acid.   
5.2.5 Liquid Chromatography and Mass Spectrometry Analyses 
Online desalting and reversed-phase chromatography was performed with a nano-
UHPLC system equipped with an autosampler (Dionex, ThermoFisher Scientific). Mobile phases 




respectively. Peptides (250 ng) were loaded onto a trapping column (100 µm i.d. x 2 cm), which 
was packed in house with C18 (3 µm, 200 Å) stationary phase material (Michrom Bioresource 
Inc,) at 3 μL*min-1 in 2% ACN with 0.1% FA for 7 min. After desalting, the sample was loaded 
onto an analytical column (100 µm i.d. x 25 cm), which was packed in-house with C18 (2.5 µm, 
150 Å, Waters).   The gradient was as follows: 0 – 10 min, 10% mobile phase B; 10 – 30 min, 10 
– 15% B; 30 – 75 min, 15 – 30% B  75 – 88 min, 30 – 60% B; 88 – 92 min, 60 – 90% B; 92 – 99 
min, 90% B; 99 – 100 min, 90 – 10% B; 100 – 120 min, 10% B. 
Standard data-dependent acquisition parameters were as follows: the MS survey scan in 
the OT (375 – 1500 m/z) was 120,000 resolution; the most intense peaks with 3s (Top Speed) 
were isolated (2 m/z) and fragmented with collision-induced dissociation (CID) in the ion trap 
with an NCE of 35%, AGC of 1 x 104, dynamic exclusion of 20 s, ppm mass tolerance of 10, 
maximum IT of 100 ms. Peptide pairs were targeted by using the targeted mass difference node. 
Two precursors were listed for the targeted group. In addition, a mass difference of 8.0444 Da 
(Heavy DM – Light DM) and 7.0381 Da (Dimethyl 7 – Light DM) were listed, the partner 
intensity range relative to the most intense precursor was set to 70 – 100 %, a subsequent scan 
was performed on both ions in the pair, and the charge state for ions in the pair had to be the 
similar. Directly after each MS/MS scan, the ten most intense fragment ions (over varying m/z 
ranges) were selected for an additional fragmentation (i.e. MS3) event by HCD and analyzed in 
the OT (scan range: 100 – 400 m/z, isolation width: 2 m/z, AGC: 5 x 104, NCE: 55%, resolution: 
60,000, maximum IT: 118 ms).  Other parameters such as precursor selection range, precursor 
ion exclusion, and isobaric tag loss exclusion were set as default. Each fraction was subject to 




5.2.6 Data Analysis  
Raw files were analyzed with PD v. 2.2 software (Thermo Scientific). Spectra were used 
to obtain sequence information against the Uniprot H. Sapiens database (06/27/18, 20319 
sequences). SEQUEST HT search parameters were as follows: two maximum trypsin 
miscleavages, precursor mass tolerance of 15 ppm, fragment mass tolerance of 1 Da; static 
modifications were either light or heavy/dimethyl 7Da Dimethyl/+28.031 or 36.028/35.070 Da 
(N-terminus) and carbamidomethyl modification/+57.021 Da (Cys); dynamic modifications were 
TMT eleven-plex/+229.163 Da (Lys) and oxidation modification/+15.995 Da (Met). Decoy 
database searching was employed to generate medium (p<0.05) confidence peptide lists. All 
peptides with medium confidence were used to identify and quantify proteins. To filter peptides, 
the following parameters were applied:  peptides with a PSM (peptide to spectral match) >1 
across biological replicates, peptide confidence level of medium, peptide rank of 1, peptide 
deviation of 10 ppm, and S/N ≥10. The reporter ions (i.e. m/z 126 – 131) were identified with the 
following parameters:  most confident centroid and 30 ppm for reporter ion mass tolerance. 
Furthermore, reporter ion values were normalized using internal reference scaling. Proteins with 
only N=3 biological replicates were used for normalization.   
To identify statistically-significant proteins, a one-way ANOVA was performed in 
Perseus software. Proteins with a p-value <0.05 and a fold-change of >1.2 or <0.83 were further 
used for bioinformatics analyses. Statistically – significant proteins were searched against 





Here, we designed a quantitative proteomics experiment (Figure 5.1) to better understand 
molecular mechanisms in the heart and liver that may contribute to AD progression. These 
tissues were compared to the brain, which is well-studied in AD, to understand similarities and 
differences across brain and peripheral tissues in AD.  Protein from brain, heart, and liver post-
mortem tissues and cognitively normal controls (N=3) were extracted and digested using 
trypsin/lys-c. Peptides from eighteen samples and four pooled samples were labeled (Table 5.2) 
at the N-terminus with light or heavy dimethylated groups and at lysine residues with TMT11-
plex (cPILOT). Labeled peptides were then pre-fractionated using SCX and analyzed by LC – 
MS/MS and MS3. 
This analysis identified 136,084 PSMs corresponding to 14,892 unique peptides and 3085 
proteins (Appendix D Tables D5.1 and D5.2). Proteins quantified (Figure 5.2a) in all tissues 
(2082, 67%) had a tremendous overlap (~99%) in brain (N=2095), heart (N=2091), and liver 
(N=2091) tissues. A marginal overlap of quantified proteins was present among brain and liver 
(N=7), heart and liver (N=1) and heart and brain (N=6). In addition, a minimal portion of 
proteins were only quantified in one tissue-type, suggesting that most proteins were present 











Figure 5.2 Protein Quantification of Brain, Heart, and Liver Tissues a) across all and b) each Biological Replicate.  
Proteins identified (N=3085) were quantified in most tissues (N=2082), with a slight increase in the brain (N=2095). 








Quantified proteins had a TMT-reporter intensity above the minimal threshold in either 
CN or AD tissue. Among quantified proteins, >60% were quantified in all biological replicates 
(Figure 5.2b) whereas 15 – 20% were quantified in one biological replicate. This range is not 
specific to one tissue type or genotype, as higher percentages of proteins quantified in one 
biological replicate is present in both AD and CN from all tissues.  
5.3.1 Hierarchical Clustering Patterns of Quantified Brain, Heart, and Liver Tissues 
Quantified proteins across CN and AD brain, heart, and liver tissues (N=3 biological 
replicates) were visualized to identify similar and different clustering patterns across tissue and 
disease state. With a stringent filter applied (average coefficient of variation <0.33 across all 
tissues), quantified proteins that met this criteria (N=147) were clustered (Figure 5.3).  CN and 
AD tissues clustered together (i.e. CN and AD brain, CN and AD heart, and CN and AD liver), 
highlighting potential differences across tissues. In the top region (Figure 5.3, zoom-in top), 
proteins are at higher levels in the heart and liver, whereas they are at lower levels in the brain. 
CN and AD levels in the region also had similar changes across these tissues. Example proteins 
in this region that follow this trend include metabolic proteins aldehyde dehydrogenase and 
isocitrate dehydrogenase (NADP), mitochondrial. In the middle region (Figure 5.3, zoom-in not 
shown), proteins were present at slightly higher levels in the heart, while at lower levels in the 
brain and liver. This region includes several proteins involved in electron transport, including 
cytochrome c oxidase, subunit 7c and cytochrome b-c1 complex subunit 1. Lastly, in the bottom 




both the heart and liver are at lower levels. Proteins that follow this trend include syntaxin 
binding protein-1 (STXBP-1) and tubulin alpha 1A chain.  
In both brain (Figure 5.4a) and heart (Figure 5.4b) tissues, protein distributions are 
similar, with comparable numbers of proteins changing at both higher and lower levels in AD. In 
the liver (Figure 5.4c), however, there was a larger percentage of proteins that changed at lower 









Figure 5.3 Hierarchical Clustering Across CN and AD Brain, Heart, and Liver Tissues. Proteins quantified with a 





Figure 5.4 Volcano Plots of Brain, Heart, and Liver Tissues. Protein distributions across a) brain, b) heart, c) liver 
tissues. Volcano plots display proteins with a fold change of >1.2 or <0.83 and a p value <0.05 (horizontal lines) 




  Among proteins that had a significant fold-change as a function of disease (AD/CN >1.2 
or < 0.83), some interesting trends were present. In the brain, few proteins met this criteria, 
whereas in the heart and liver, many proteins were expressed at lower or higher levels. Tissue 
samples, per biological replicate, originated from the same person, therefore a system-wide 
analysis of these tissues could be profiled. Selected proteins differentially – expressed in AD 
compared to CN (in at least one tissue) were compared across tissues (Figure 5.5). Both cAMP-
dependent protein kinase type II-beta regulatory subunit (CAAP-1, Figure 5.5a) and syntaxin-
binding protein 1 (STXBP-1, Figure 5.5b) were quantified at higher levels in the brain and at 
lower levels in both the heart and liver. In both proteins, AD levels compared to CN were lower 
in the brain (CAAP-1: 0.88 ± 0.64, STXBP-1: 0.81± 0.054) while higher in the heart (CAAP-1: 
1.96 ± 0.94, STXBP-1: 1.27 ± 0.69). In the liver, these proteins were at either higher (1.47 ± 
0.88) or lower (0.79 ± 0.29) levels.  In hemoglobin protein beta (HBB, Figure 5.5c), proteins 
were at higher levels in the brain (1.24 ± 0.23) while at lower levels in the liver (0.77 ± 0.21); in 
the heart, proteins levels were more abundant than in the liver, but at similar levels in AD 
compared to CN (1.08 ± 0.38). Lastly, in both cytochrome b-c1 complex subunit 1, 
mitochondrial (Figure 5.5d) and thioredoxin-related transmembrane protein 4 (Figure 5.5e), 
Protein levels in AD compared to CN were lower in both the brain (UQCRC1: 0.82 ± 0.17, 
TMX-4: 0.77 ± 0.34) and liver (UQCRC1: 0.79 ± 0.24, TMX-4: 0.68 ± 0.088. However, AD 





Figure 5.5 Trends of Statistically – Significant Proteins in Brain, Heart, and Liver Tissues. Whisker plots of 










Table 5.3 Differentially – Expressed Proteins in the Brain, Heart, and/or Liver. 
Accession Protein Description (short) AD/CN Brain p-value brain AD/CN Heart p-value heart AD/CN Liver p-value liver
P61981 14-3-3 protein gamma 0.98 ± 0.065 0.84 1.28 ± 0.20 0.038 0.85 ± 0.20 0.61
Q6NVY1 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 0.99 ± 0.060 0.97 1.46 ± 1.4 0.50 0.78 ± 0.089 0.020
P25398 40S ribosomal protein S12 0.95 ± 0.11 0.71 0.99 ± 0.41 0.96 0.73 ± 0.050 0.039
P08708 40S ribosomal protein S17 1.20 ± 0.39 0.38 1.07 ± 0.59 0.78 0.70 ± 0.054 0.010
P23396 40S ribosomal protein S3 0.97 ± 0.15 0.79 1.16 ± 0.74 0.76 0.78 ± 0.060 0.013
P18124 60S ribosomal protein L7 1.02 ± 0.51 0.95 1.13 ± 0.78 0.78 0.69 ± 0.054 0.035
Q02952 A-kinase anchor protein 12 1.16 ± 0.019 0.46 1.11 ± 0.41 0.56 0.78 ± 0.15 0.042
P02763 Alpha-1-acid glycoprotein 1 0.85 ± 0.67 0.66 0.90 ± 0.14 0.76 0.77 ± 0.064 0.019
P01009 Alpha-1-antitrypsin 0.83 ± 0.35 0.67 1.32 ± 0.56 0.49 0.54 ± 0.082 0.0015
P63010 AP-2 complex subunit beta 0.78 ± 0.25 0.24 1.14 ± 0.49 0.51 0.78 ± 0.16 0.048
O14617 AP-3 complex subunit delta-1 0.96 ± 0.21 0.82 0.91 ± 0.029 0.64 0.71 ± 0.069 0.022
O00571 ATP-dependent RNA helicase DDX3X 0.90 ± 0.12 0.30 1.67 ± 0.39 0.0062 0.52 ± 0.38 0.21
P02730 Band 3 anion transport protein 0.72 ± 0.33 0.28 1.26 ± 0.16 0.033 1.31 ± 0.35 0.22
O75531 Barrier-to-autointegration factor 0.69 ± 0.34 0.36 1.04 ± 0.68 0.92 0.63 ± 0.22 0.038
P35613 Basigin 0.93 ± 0.15 0.46 0.83 ± 0.24 0.26 0.73 ± 0.14 0.028
P19022 Cadherin-2 0.62 ± 0.18 0.21 1.35 ± 0.44 0.12 0.60 ± 0.18 0.020
O75746 Calcium-binding mitochondrial carrier protein Aralar1 1.10 ± 0.16 0.24 0.73 ± 0.14 0.048 0.56 ± 0.46 0.42
Q9HB71 Calcyclin-binding protein 0.83 ± 0.32 0.46 1.01 ± 0.33 0.98 0.66 ± 0.16 0.019
P31323 cAMP-dependent protein kinase type II-beta regulatory subunit 0.81 ± 0.25 0.22 1.56 ± 0.16 0.010 0.82 ± 0.19 0.16
P00918 Carbonic anhydrase 2 1.33 ± 0.20 0.022 1.13 ± 0.12 0.54 1.25 ± 0.47 0.25
Q9H8G2 Caspase activity and apoptosis inhibitor 1 0.88 ± 0.64 0.80 1.96 ± 0.94 0.031 1.47 ± 0.88 0.48
P35221 Catenin alpha-1 0.89 ± 0.23 0.68 1.36 ± 0.78 0.29 0.76 ± 0.087 0.030
Q8N126 Cell adhesion molecule 3 0.82 ± 0.11 0.021 1.14 ± 3.0 0.85 0.42 ± 0.86 0.19
Q00610 Clathrin heavy chain 1 0.83 ± 0.16 0.10 1.14 ± 0.55 0.56 0.76 ± 0.16 0.045
P53618 Coatomer subunit beta 0.88 ± 0.30 0.66 1.03 ± 0.38 0.86 0.70 ± 0.092 0.042
P10643 Complement component C7 0.90 ± 0.58 0.69 0.92 ± 0.50 0.78 0.57 ± 0.034 0.0061
P31930 Cytochrome b-c1 complex subunit 1, mitochondrial 0.82 ± 0.17 0.11 0.71 ± 0.034 0.00012 0.77 ± 0.24 0.14
P14927 Cytochrome b-c1 complex subunit 7 0.85 ± 0.20 0.17 0.76 ± 0.11 0.020 0.63 ± 0.14 0.05
P09669 Cytochrome c oxidase subunit 6C 0.95 ± 0.094 0.45 0.79 ± 0.25 0.18 0.50 ± 0.066 0.032
P14406 Cytochrome c oxidase subunit 7A2, mitochondrial 0.99 ± 0.36 0.96 0.76 ± 0.17 0.17 0.66 ± 0.052 0.0024
P15954 Cytochrome c oxidase subunit 7C, mitochondrial 0.86 ± 0.21 0.31 0.51 ± 0.092 0.0094 0.70 ± 0.21 0.23
P07585 Decorin 0.94 ± 0.63 0.87 1.70 ± 0.41 0.0075 1.38 ± 0.97 0.49
Q9UI17 Dimethylglycine dehydrogenase, mitochondrial 1.36 ± 1.5 0.61 1.08 ± 1.0 0.82 0.62 ± 0.086 0.013
P11532 Dystrophin OS 0.60 ± 0.20 0.27 1.18 ± 0.80 0.67 0.68 ± 0.21 0.046
Q15075 Early endosome antigen 1 1.25 ± 0.64 0.51 1.15 ± 0.68 0.75 0.45 ± 0.18 0.043
Q6UWR7 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1.09 ± 0.29 0.70 0.78 ± 0.015 0.14 0.69 ± 0.12 0.033
Q9BY44 Eukaryotic translation initiation factor 2A 0.96 ± 0.37 0.81 0.99 ± 0.79 0.97 0.61 ± 0.11 0.0066
Q16658 Fascin 0.91 ± 0.24 0.50 1.33 ± 0.66 0.35 0.79 ± 0.059 0.0051
P30043 Flavin reductase (NADPH) 1.18 ± 0.37 0.23 1.20 ± 0.14 0.034 1.18 ± 0.11 0.50
P56470 Galectin-4 1.88 ± 0.24 0.029 1.39 ± 1.6 0.51 1.04 ± 0.92 0.92
Q9UEY8 Gamma-adducin 1.04 ± 0.21 0.81 0.98 ± 0.40 0.91 0.67 ± 0.061 0.0046
P68871 Hemoglobin subunit beta 1.24 ± 0.23 0.23 1.08 ± 0.38 0.58 1.49 ± 0.21 0.049
Q5SSJ5 Heterochromatin protein 1-binding protein 3 1.03 ± 0.24 0.81 0.95 ± 0.33 0.78 0.73 ± 0.10 0.010
Q99729 Heterogeneous nuclear ribonucleoprotein A/B 1.02 ± 0.61 0.94 0.96 ± 0.36 0.85 0.72 ± 0.085 0.034
O60506 Heterogeneous nuclear ribonucleoprotein Q 0.93 ± 0.11 0.59 0.87 ± 0.58 0.60 0.71 ± 0.12 0.034
Q9UJM8 Hydroxyacid oxidase 1 1.48 ± 1.9 0.45 0.98 ± 1.1 0.96 0.66 ± 0.15 0.028
A0A0C4DH68 Immunoglobulin kappa variable 2-24 0.74 ± 0.43 0.41 0.57 ± 0.25 0.08 0.46 ± 0.16 0.0053
Q14894 Ketimine reductase mu-crystallin 1.07 ± 0.49 0.73 0.58 ± 0.38 0.29 0.65 ± 0.084 0.0012
Q6P1M0 Long-chain fatty acid transport protein 4 0.90 ± 0.14 0.50 1.33 ± 1.3 0.39 0.68 ± 0.12 0.017
Q15046 Lysine--tRNA ligase 1.17 ± 0.49 0.38 0.99 ± 0.37 0.96 0.67 ± 0.14 0.020
P11279 Lysosome-associated membrane glycoprotein 1 1.12 ± 0.12 0.14 1.01 ± 0.35 0.95 0.77 ± 0.15 0.040
P40926 Malate dehydrogenase, mitochondrial 0.95 ± 0.024 0.25 0.94 ± 0.28 0.68 0.73 ± 0.15 0.031
P55157 Microsomal triglyceride transfer protein large subunit 1.37 ± 1.17 0.46 1.22 ± 1.6 0.74 0.79 ± 0.014 0.044
P27816 Microtubule-associated protein 4 0.97 ± 0.21 0.77 1.15 ± 0.38 0.34 0.67 ± 0.11 0.019
Q9UPY8 Microtubule-associated protein RP/EB family member 3 0.89 ± 0.49 0.59 0.54 ± 0.094 0.034 0.48 ± 0.40 0.09
Q02978 Mitochondrial 2-oxoglutarate/malate carrier protein 0.90 ± 0.066 0.26 0.67 ± 0.064 0.013 1.11 ± 0.13 0.68
Q9Y276 Mitochondrial chaperone BCS1 0.98 ± 0.33 0.89 0.96 ± 0.64 0.89 0.71 ± 0.087 0.0059
Q9NXA8 NAD-dependent protein deacylase sirtuin-5, mitochondrial 0.81 ± 0.31 0.59 0.99 ± 0.72 0.99 0.60 ± 0.12 0.032
Q6PIU2 Neutral cholesterol ester hydrolase 1 0.88 ± 0.19 0.23 1.20 ± 0.092 0.0064 0.71 ± 0.25 0.20
Q0ZGT2 Nexilin 1.13 ± 0.60 0.68 0.87 ± 0.16 0.31 0.71 ± 0.21 0.046
P06748 Nucleophosmin 0.89 ± 0.26 0.66 1.57 ± 0.37 0.035 0.69 ± 0.31 0.29
P40855 Peroxisomal biogenesis factor 19 1.01 ± 0.21 0.94 1.10 ± 0.69 0.78 0.71 ± 0.087 0.0094
Q9UPV7 PHD finger protein 24 0.66 ± 0.23 0.23 1.39 ± 1.9 0.63 0.61 ± 0.19 0.042
O15212 Prefoldin subunit 6 1.20 ± 0.46 0.48 1.62 ± 0.60 0.019 0.77 ± 0.16 0.38
P07237 Protein disulfide-isomerase 1.31 ± 1.3 0.65 1.07 ± 0.063 0.83 0.60 ± 0.063 0.031
Q15084 Protein disulfide-isomerase A6 0.91 ± 0.46 0.73 0.96 ± 0.42 0.82 0.63 ± 0.0090 0.021
Q15404 Ras suppressor protein 1 0.89 ± 0.21 0.43 1.32 ± 0.35 0.09 0.69 ± 0.16 0.015
Q9H0U4 Ras-related protein Rab-1B 0.75 ± 0.11 0.030 1.12 ± 0.47 0.65 0.69 ± 0.22 0.075
Q00266 S-adenosylmethionine synthase isoform type-1 1.78 ± 2.5 0.51 1.07 ± 1.0 0.92 0.65 ± 0.14 0.0067
P67775 Serine/threonine-protein phosphatase 2A catalytic subunit alpha 1.01 ± 0.13 0.94 0.73 ± 0.070 0.025 0.84 ± 0.075 0.35
Q13813 Spectrin alpha chain, non-erythrocytic 1 0.86 ± 0.23 0.34 1.19 ± 0.44 0.42 0.70 ± 0.17 0.032
Q01082 Spectrin beta chain, non-erythrocytic 1 0.84 ± 0.19 0.27 1.05 ± 0.27 0.70 0.72 ± 0.11 0.0080
P63208 S-phase kinase-associated protein 1 0.91 ± 0.13 0.20 1.00 ± 0.36 0.98 0.68 ± 0.15 0.022
Q9GZT3 SRA stem-loop-interacting RNA-binding protein, mitochondrial 0.69 ± 0.17 0.27 1.09 ± 0.60 0.72 0.55 ± 0.13 0.012
Q9UJZ1 Stomatin-like protein 2, mitochondrial 1.05 ± 0.34 0.77 0.79 ± 0.082 0.048 1.18 ± 0.23 0.56
P08247 Synaptophysin 0.85 ± 0.14 0.50 1.90 ± 0.62 0.016 0.69 ± 0.40 0.31
P61764 Syntaxin-binding protein 1 0.81 ± 0.054 0.014 1.27 ± 0.69 0.36 0.79 ± 0.29 0.24
Q9Y490 Talin-1 1.06 ± 0.46 0.75 1.00 ± 0.34 1.0 0.73 ± 0.091 0.013
Q9H1E5 Thioredoxin-related transmembrane protein 4 0.77 ± 0.34 0.26 1.35 ± 0.19 0.048 0.68 ± 0.088 0.0050
Q92544 Transmembrane 9 superfamily member 4 0.99 ± 0.41 0.97 1.43 ± 1.0 0.30 0.67 ± 0.12 0.013
P49755 Transmembrane emp24 domain-containing protein 10 1.05 ± 0.46 0.82 1.40 ± 0.73 0.25 0.63 ± 0.089 0.019
Q92973 Transportin-1 1.00 ± 0.13 0.98 1.00 ± 0.32 0.99 0.78 ± 0.13 0.028
P61088 Ubiquitin-conjugating enzyme E2 N 1.01 ± 0.14 0.85 1.02 ± 0.18 0.83 0.83 ± 0.067 0.028
P61960 Ubiquitin-fold modifier 1 0.85 ± 0.19 0.48 1.19 ± 1.4 0.75 0.75 ± 0.081 0.048
Q9Y4I1 Unconventional myosin-Va 0.68 ± 0.42 0.33 1.06 ± 0.53 0.75 0.66 ± 0.23 0.046
P54289 Voltage-dependent calcium channel subunit alpha-2/delta-1 0.86 ± 0.20 0.29 1.07 ± 0.88 0.83 0.61 ± 0.066 0.0058
O75083 WD repeat-containing protein 1 0.89 ± 0.13 0.47 1.02 ± 0.44 0.95 0.75 ± 0.17 0.048




5.3.2 Canonical pathways Associated with Differentially – Expressed Proteins 
Differentially – expressed proteins (p value <0.05 and AD/CN >1.2 or <0.83) in the brain 
(N=5), heart (N=20), and liver (N=62) were searched in IPA to identify significant canonical 
pathways, molecular functions, and cellular components. As there were few significant brain 
proteins, no pathways were identified, however, molecular functions related to the cell signaling 
and interaction, assembly and organization, and survival and death were identified. In the heart 
(Figure 5.6), the most significant pathways were related to oxidative phosphorylation and 
mitochondrial dysfunction whereas in the liver (Figure 5.7) pathways related to elongation factor 
2 signaling and unfolded protein response were identified. Significant molecular functions across 
these tissues were related to cell function and protein synthesis, with specific functions related to 
molecular transport in the heart and RNA damage and repair in the liver. With a relaxed filter 
(i.e. AD/CN >1.2 or <0.83 only), the pathway mitochondrial dysfunction and molecular function 
protein synthesis was significant across all tissues. Proteins in the heart and liver, furthermore, 
had an increase of similar molecular functions, including those related to cell assembly and 
organization and molecular transport. In addition, this relaxed filter identified 18 proteins related 
to Alzheimer’s disease at higher (e.g. Synaptophysin, STXBP-1, and CAAP-1) or lower (e.g. 
superoxide dismutase [Mn], mitochondrial, alpha-1 antichymotrypsin, and vacuolar protein 
sortin-associated protein 35: VPS-35) levels in the heart. In the brain, proteins related to 
amyloidosis (N=12) were at higher (e.g. gelsolin and microtubule-associated protein 2) or lower 
(e.g. STXBP-1) levels and in the liver (N=25), proteins (e.g. eukaryotic translation initiation 
factor 2A, VPS-35, and signal transducer and activator of transcription 3) associated with the 





















Recently, we studied AD pathogenesis in brain, heart, and liver tissues in a 14-month-old 
APP/PS-1 mouse model (Chapter 4), in which changes related to energy metabolism were 
identified across tissues. Biological processes identified from brain and liver proteins overlapped 
with pathways related to carbohydrate and lipid metabolism, whereas heart proteins were related 
to protein translation. While that study provided some insight into the contribution of liver and 
heart peripheral tissues to AD progression, limitations were evident. The APP/PS-1 mouse model 
is based on early-onset AD, therefore, it does not directly correlate to changes occurring in late-
onset AD.  This model includes the presence of Aβ plaques, however, it does not have the 
presence of neurofibrillary tangles. To bridge this gap in understanding, postmortem human 
brain (superior frontal gyrus), heart, and liver tissues from AD (N=3, Braak stages IV and V) and 
cognitively normal (CN) controls (N=3) were analyzed using quantitative proteomics. Tissue 
samples were each from one person, therefore system-wide changes were able to be followed 
within each individual and across biological replicates. Using cPILOT allowed all samples to be 
uniquely labeled and subsequently analyzed simultaneously. This reduced potential experimental 
error and analysis time while increasing sample throughput. In addition, a single analysis allows 
for direct comparison of all tissues within one experimental analysis therefore, changes occurring 
across disease state and tissue-type can be compared.  
Factors to take into consideration during sample preparation are related to tissue 
homogenization and protein concentration. Different homogenization times were necessary to 
extract protein from tissues. Since the heart is a muscular organ, it require additional intervals to 




concentration assay. As the tissues varied in concentration, dilutions were adjusted in order to 
successfully determine protein amounts. 
5.4.1 Protein Clustering Across Brain, Heart, and Liver Tissues 
Proteins that were quantified in all biological replicates and that had an average 
CV<0.33, were compared to determine similarities across both disease-state and tissue-type. A 
few notable trends were present across AD and CN tissues, including regions where 1) brain 
proteins were at lower levels than both the liver and heart (Figure 5.3, zoom-in top), 2) heart 
proteins were present at higher levels than both the brain and liver (Figure 5.3, middle region), 
and 3) brain proteins were present at higher levels in comparison to both the liver and heart 
(Figure 5.3, zoom-in bottom). In the top region, all biological processes were related to 
metabolism, specifically, catabolic processes involved in glycolysis, the Krebs cycle, amino acid, 
lipid, and alcohol metabolism. Interestingly proteins involved in translation and protein folding 
were also grouped together. Ribosomal and other translational proteins are known to decrease in 
the brain as a function of AD progression and proteins in this group behave similarly.217-218 
Conversely, these levels increased in the heart after disease which may imply that AD 
progression does not affect the ability of the heart to synthesize proteins. Similar to the top 
region, proteins in the middle region (not shown) were also mainly involved in metabolism with 
an increase of proteins related to electron transport. Several electron transport proteins (i.e. 
cytochrome c and cytochrome b) are differentially – expressed in the heart, which has not been 
previously reported in AD. Dysfunctions in this part of energy metabolism are related to 




mostly related to transport, localization, and cell function. Transport proteins clathrin heavy 
chain 1 (CLTC) and vacuolar protein sorting-associated protein-35 (VPS-35) are involved in 
transporting type-1 transmembrane proteins (e.g. APP and β-site APP cleaving enzyme, BACE) 
between the cell surface, endosome and trans-golgi network, and are critical to maintaining 
normal cell function.174 VPS-35, specifically, is present in the brain at high levels in cognitively 
normal individuals while declining during AD progression; in this study, VPS-35 was present at 
levels two times higher in both the heart and the liver of AD, but at slight lower levels in the 
brain.  
5.4.2 Differentially – Expressed Post-Mortem Brain and Peripheral Tissues 
In this experiment, samples from the superior frontal gyrus were kindly provided (Banner 
Sun Health Research Institute), to benchmark changes as a function of disease to heart and liver 
tissues. In AD, differentially – expressed proteins were related to several types of cellular 
molecular functions. Rab 1 and syntaxin binding protein 1 are involved in protein transport174, 220-
221 and binding and changed significantly at higher levels in AD.  The lack of significant proteins 
from brain tissues may indicate minor AD pathology in this region during Braak stage IV. SFG 
has not been reported to change drastically in AD.222 However, as this region is involved in 
executive functions, conditions such as frontal temporal dementia (FTD) or frontal variant AD 
(fvAD) may have elicited a more profound response.223-225   
In the heart, several proteins related to oxidative phosphorylation, mitochondrial 
dysfunction, and cell signaling were differentially – expressed. Cytochrome proteins, which are 




electron transport chain are hypothesized to contribute cardiovascular disease226 and in AD, it 
may contribute to disease pathogenesis by causing an increase of mitochondrial dysfunction. 
Transport proteins in the solute carrier family (e.g. SLC4A-1, SLC25A-12, SLC25A-11) 
changed significantly at higher (SLC4A-1) or lower (SLC25A-12 and SLC25A-11) levels. As 
protein transport is necessary for protein function and has been noted to be dysregulated in AD, 
they may contribute to mitochondrial dysfunction.174 Lastly, proteins involved in apoptosis and 
immunity, including CAAP-1, dead-box helicase, nucleophosmin, and serine/threonine-protein 
phosphatase 2A catalytic subunit alpha were differentially – expressed in AD. Dysregulated 
apoptosis has been implicated in AD.227 Overall, the identification of significant proteins CAAP-
1 and Synaptophysin-1 was especially interesting, as these proteins have been implicated 
previously in AD pathogenesis.228-230   
Differentially – expressed liver proteins were related to signaling and unfolded protein 
response. Some proteins in these pathways included clathrin-related transport proteins alpha-1-
acid glycoprotein 1 (ORM-1), alpha-1-antitrypsin (SERPIN-A1), AP-2 complex subunit beta 
(AP-2B), and CLTC-1, which were at lower levels in AD. Clathrin-mediated endocytosis is 
involved in transporting transmembrane proteins to and from the endosome and dysregulation 
has been implicated in AD.174 Proteins involved in translation or protein folding were also 
significant at lower levels in liver tissues. As protein synthesis and folding is known to be 
dysregulated in AD brain pathology, these changes in the liver may be evident of similar patterns 
present across these tissues. 
Across tissues, significant changes were most evident in comparisons of brain vs. heart 
and brain vs. liver. In both AD and CN tissues, differentially – expressed proteins were mostly 




vs. heart and were involved in electron transport, carbohydrate metabolism, transport, and 
protein translation. The lack of significant changes between liver and heart tissues may note 
similarities between the behavior of these tissues in both AD and healthy states. 
5.5 CONCLUSIONS 
A comparative analysis across brain, heart, and liver tissues was performed to understand 
how peripheral liver and heart tissues are involved in AD pathogenesis. In the heart, a decrease 
of electron transport activity along with an increase of protein binding and apoptosis occurs. In 
the liver, a decrease of many pathways including translation, protein folding, and transport were 
present. Though few differentially – expressed proteins overlapped across the tissues, there were 
similarities in the pathways. A similar trend was also seen in Chapter 4, which analyzed a 
mouse model of AD. In that dataset, most proteins were also only significant in one tissue. When 
comparing statistically – significant proteins across both organisms, there was minimal overlap. 
Among the 354 proteins that were quantified in both datasets, several proteins had similar fold-
change values in AD compared to WT (mouse) or CN (human), however, the number of 
differentially – expressed proteins varied. This resulted in statistically – significant proteins only 
being present in one organism type. In the future, a larger batch of samples will be tested to gain 





6.0 SUMMARY AND FUTURE DIRECTIONS 
6.1 SUMMARY 
Here, multiplexing techniques have been employed across several organisms to 
understand aging, infection and Alzheimer’s disease (AD). In each analysis, multiplexing was 
used to analyze several samples simultaneously, thus improving sample throughput by reducing 
sample analysis time and potential experimental error. In Chapter 2, multiplexing efforts 
allowed for the direct comparison of young and aging adult Caenorhabditis elegans (C. elegans) 
exposed to the opportunistic pathogen Pseudomonas aeruginosa (P. aeruginosa strain PA01).  
Each population had unique and shared responses to infection including pathways related to 
metabolism, development, locomotion and structure. In addition, both C. elegans exposed to P. 
aeruginosa PA01 and aging C. elegans presented higher levels of oxidative stress. To assess the 
performance of a higher performing instrument, C. elegans samples were ran on an Orbitrap 
Elite mass spectrometer in Chapter 3. Less proteins and peptides were identified from the more 
advanced instrument (i.e. the Elite) thus leading us to propose that a combination of factors that 
were not in reference of the instrument, including limited sample and experimental error, may 
have contributed to a decrease of C. elegans proteins identified. In order to analyze >12 samples, 
a different multiplexing technique, combined precursor isotopic labeling and isobaric tagging  




amyloid precursor protein/presenilin-1 (APP/PS-1) mice. With using both Orbitrap Velos and 
Fusion Lumos MS platforms, changes heavily involved in metabolism were identified across 
tissues as a function of disease. In addition, an optimized method to analyze cPILOT samples 
was developed on the Fusion Lumos, which was also applied in Chapter 5. In this chapter, a 
similar analysis was performed as in Chapter 4. Peripheral (i.e. heart and liver) and brain 
proteomes of AD and cognitively normal (CN) post-mortem tissues were analyzed by using 
cPILOT. Interestingly, changes related to transport, protein translation and folding, apoptosis and 
immunity, and metabolism were found to be significant, highlighting ways the periphery may be 
involved in AD pathogenesis.  
Overall, findings from this work highlight the usage of multiplexing and its applications 
to infection and disease-related biological problems.  
6.2 FUTURE DIRECTIONS 
Future analyses of cPILOT include studying oxidative modifications. In Chapter 2, one 
of the most defined changes of young- and aging adult C. elegans exposed to pathogen was the 
presence of oxidative stress. Oxidative stress is accompanied by oxidative modifications to 
proteins, which can impair structure and ultimately protein function. To understand oxidative 
modifications in C. elegans, an in vivo oxidation model was applied. Fast photochemical 
oxidation of proteins (FPOP) is a hydroxyl radical foot printing method that uses a pulsed laser 
for the photolysis of hydrogen peroxide.231 This technique irreversibly modifies amino acids and 




FPOP/IV-FPOP), successfully modifying most (i.e. 16) amino acids.232-233 In this application, C. 
elegans are labeled by IV-FPOP and is compared to control and C. elegans oxidized by hydrogen 
peroxide (control oxidation). This application requires testing three factors (i.e. FPOP, control 
oxidation, control) such that an experiment containing three biological replicates and two 
technical replicates increases the total number of samples for analysis to eighteen. Currently, 
samples are analyzed individually, which requires extensive sample preparation and analysis 
time. To increase the throughput of this experiment, C. elegans samples labeled by IV-FPOP can 
be further labeled by cPILOT.  
A preliminary proof-of-concept study has been employed to tests the combination of 
cPILOT and FPOP. Similar to experiments in Chapters 4 and 5, protein was extracted from C. 
elegans homogenate and digested with trypsin. Peptides were labeled by light- or heavy 
dimethylation at the N-terminus and TMT10-plex tags at lysine residues. A pooled sample was 
fractionated by SCX and analyzed by LC – MS/MS and MS3 on an Orbitrap Fusion Lumos. Raw 
data generated was searched in PD and results were analyzed manually to calculate FPOP 
oxidations. Preliminary data identified over >180,000 PSMs, corresponding to 2682 proteins 
(Table 6.1). Most lysine terminated light- and heavy-dimethylated peptides were labeled by TMT 
(i.e. 98%) and >60% of proteins (i.e. 67 and 65%) were quantified in all channels. Additionally, 
560 proteins had oxidative modifications, of which 484 proteins (i.e. 86%) were also quantified 




Table 6.1 Protein and Peptide Results of a FPOP-cPILOT Experiment. 
Protein Groups
Protein Groups      
(10 channels, %)a PSMs ID R (%)b K (%)c TMT-K (%)d
Light DM 2334 1553 (66.5%) 88528 18322 (20.7) 69393 (78.4) 67811 (97.7)
Heavy DM 2193 1426 (65.0%) 92077 17652 (19.2) 73398 (79.7) 71726 (97.7)
a The number and percentage of proteins quantified across all reporter ion channels (i.e. 126-131).  bThe number and 
percentage of peptides ending with arginine.  cThe number and percentage of peptides ending with lysine. dThe number and 




Aspects of this experiment to take into consideration are related to data analysis. As 
samples are labeled by both FPOP and cPILOT, search parameters have to be adjusted for both 
sets of modifications. Proteins labeled by FPOP can have several types of oxidative 
modifications, including carbonylation (+14 Da), oxidation (+16), dioxidation (+32), and 
trioxidation (+47)232; peptides labeled by cPILOT are modified at the N-terminus by light or 
heavy dimethylation (+28.032 or +36.036/35.070) and at lysine residues by TMT10-plex 
(+229.163). This results in extended search times (i.e. 12 – 24 h). In order to search efficiently, 
both sets of parameters were combined into several nodes, thus reducing searching time to (9 – 
16 h).  
Overall, this proof-of-concept experiment showed that IV-FPOP samples could 
successfully be labeled by cPILOT. This is advantageous as it allows proteome-wide structural 
biology to be conducted in this model organism in a high-throughput manner. Future applications 
(Figure 6.1) include labeling young-adult C. elegans exposed to pathogen and wild-type controls 
with IV-FPOP and multiplexing with cPILOT. As an additional factor (i.e. disease-state) could 
be added to this experiment and the minimal number of samples could double to 36. This will 
require at least two cPILOT batches or a 36-plex cPILOT platform. The gain in experimental 
throughput will be accompanied by an increase in the complexity of sample preparation and data 
analysis. It will be imperative to handle samples properly and perform labeling of cPILOT 
samples in intervals to ensure similar labeling times. Once data is searched in PD, result files can 
be merged into one dataset and data can be analyzed (i.e. data normalization, statistical tests, and 
bioinformatics analyses). This application and others of cPILOT will show the versatility of this 




such an experiment will allow us to better understand the impact of oxidative stress upon 
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Appendix A Table A2.1 Pathogenicity Assays 
Day 1 (Biological Replicate 1)
Bacteria Mean ±SE n P-value (vs. OP50)
E. coli  OP50 18.5 0.3 65/71 N/A
P. aeruginosa  PA01 14.4 0.2 80/84 <0.0001
Day 1 (Biological Replicate 2)
Bacteria Mean ±SE n P-value (vs. OP50)
E. coli  OP50 18.7 0.42 39/44 N/A
P. aeruginosa  PA01 11.2 0.58 41/49 0
Day 5 (Biological Replicate 1)
Bacteria Mean ±SE n P-value (vs. OP50)
E. coli  OP50 18.6 0.2 97/108 N/A
P. aeruginosa  PA01 10.4 0.08 90/90 <0.0001
Day 5 (Biological Replicate 2)
Bacteria Mean ±SE n P-value (vs. OP50)
E. coli  OP50 21.9 0.65 36/46 N/A
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